Conditions: Tourette Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 124
Healthy volunteers: no

Brief summary:
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 8 weeks of treatment. This study will enroll approximately 90 male and female subjects clinically diagnosed with Tourette Syndrome.

Detailed description:

Arms:
arm 1: Placebo administered once daily for 8 weeks arm 2: Fixed dose administered once daily for 8 weeks arm 3: Fixed dose administered once daily for 8 weeks

Interventions: intervention 1: NBI-98854 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document:
Prot_000.pdf: 
1. 
TITLE PAGE 
 
 
CLINICAL STUDY PROTOCOL 
 
Protocol Amendment 3 Version Date:  29 June 2016 
Protocol Amendment 2 Version Date:  29 October 2015 
Protocol Amendment 1 Version Date:  19 October 2015 
Original Final Version Date:  23 June 2015 
 
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety 
and Efficacy of NBI-98854 in Adult Subjects with Tourette Syndrome 
 
Study No.:  NBI-98854-1505 
 
 
Development Phase:  Phase 2 
 
 
Sponsor: 
 
Neurocrine Biosciences, Inc. 
 
12780 El Camino Real 
 
San Diego, CA 92130 
 
Telephone:  (858) 617-7600 
 
Facsimile:    (858) 617-7705 
 
CONFIDENTIAL 
This document is a confidential communication of Neurocrine Biosciences, Inc.  It is agreed that 
no unpublished information contained herein will be published or disclosed without prior 
approval from the sponsor.  However, this document can be disclosed to an appropriate 
Institutional Review Board/Ethics Committee (IRB/EC) or authorized representatives of national 
regulatory authorities under the condition that they respect its confidential nature. 


SIGNATURES: 
I agree to conduct this study in accordance with the requirements of this clinical study protocol 
and also in accordance with the following: 
• Established principles of Good Clinical Practices (GCP) (Harmonized) 
• United States (US) Code of Federal Regulations (CFR); US Food and Drug Administration 
(FDA) 
 
CLINICAL STUDY TITLE: 
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of 
NBI-98854 in Adult Subjects with Tourette Syndrome 
 
PROTOCOL No.: 
NBI-98854-1505 
 
As Agreed: 
 
____________________________________ 
_______________________ 
Principal Investigator Signature 
Date 
 
PRINCIPAL INVESTIGATOR: 
 
______________________________________________________________ 
(Print Principal Investigator Name) 
 
SITE:   
 
________________________________________________________ 
(Print Site Name) 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 2


Neurocrine Biosciences, Inc., Study No. NBl-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version 
Accepted for the Sponsor: 
SPONSOR: 
Date 
29 June 2016 
Neurocrine Biosciences, Inc. 
12780 El Camino Real 
San Diego, CA 92130 
Phone: (858) 617-7600 
Facsimile: (858) 617-7705 
Chris O'Brien, MD 
Chief 
Officer 
Confidential 
Page J 


LIST OF SPONSOR PERSONNEL 
Neurocrine Biosciences, Inc. 
12780 El Camino Real 
San Diego, CA 92130 
Medical Monitor:  
Telephone:(858)
7250 
Facsimile:  
Cell Phone: 
Sr. Director, Clinical Development:  
Telephone:(858)
7719 
Facsimile:  
Serious Adverse Event Reporting: 
Telephone:   (866) 626-7792 or (858) 617-7792 
Facsimile:  
(888) 617-7551 
Email:  
 
cds@neurocrine.com 
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 4


TABLE OF CONTENTS  
1. 
TITLE PAGE ................................................................................................. 1 
2. 
SYNOPSIS .................................................................................................... 9 
3. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.............. 12 
4. 
ETHICS ....................................................................................................... 14 
5. 
INTRODUCTION ....................................................................................... 14 
5.1. 
Background .................................................................................................. 14 
5.2. 
NBI-98854 ................................................................................................... 15 
5.3. 
Study and Dose Rationale ............................................................................ 17 
6. 
STUDY OBJECTIVES ............................................................................... 18 
7. 
OVERVIEW OF STUDY DESIGN ............................................................ 18 
7.1. 
Study Design ................................................................................................ 18 
8. 
STUDY POPULATION .............................................................................. 20 
8.1. 
Inclusion Criteria ......................................................................................... 20 
8.2. 
Exclusion Criteria ........................................................................................ 21 
8.3. 
Subject Identification and Replacement ...................................................... 23 
8.4. 
Randomization ............................................................................................. 23 
9. 
STUDY EVALUATIONS ........................................................................... 23 
9.1. 
Schedule of Assessments ............................................................................. 23 
9.2. 
Screening and Baseline Assessments .......................................................... 25 
9.2.1. 
Genotyping .................................................................................................. 25 
9.3. 
Efficacy Assessments .................................................................................. 25 
9.3.1. 
Yale Global Tic Severity Scale.................................................................... 25 
9.3.2. 
Rush Video-Based Tic Rating Scale............................................................ 26 
9.3.3. 
Premonitory Urge for Tics Scale ................................................................. 26 
9.3.4. 
Clinical Global Impression of Tourette Syndrome ...................................... 26 
9.4. 
Pharmacokinetic Evaluations ....................................................................... 27 
9.5. 
Safety Assessments ...................................................................................... 27 
9.5.1. 
Vital Sign Measurements ............................................................................. 27 
9.5.2. 
Medical History ........................................................................................... 28 
9.5.3. 
Physical Examination, Including Height and Weight .................................. 28 
9.5.4. 
Electrocardiogram ........................................................................................ 28 
9.5.5. 
Clinical Laboratory Assessments ................................................................ 28 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 5


9.5.6. 
Columbia-Suicide Severity Rating Scale ..................................................... 29 
9.5.7. 
Extrapyramidal Symptom Rating Scale-Abbreviated ................................. 30 
9.5.8. 
Structured Interview Guide for the Hamilton Depression Rating Scale ...... 30 
9.5.9. 
Estimated Total Blood Sample Volume Required by Study ....................... 30 
9.6. 
Specific Study Information .......................................................................... 31 
9.6.1. 
Screening (Days -21 to -2) ........................................................................... 31 
9.6.2. 
Baseline (Day -1) ......................................................................................... 31 
9.6.3. 
Treatment Period:  Weeks 2, 4, 6, and 8 (±3 days for each visit) ................ 33 
9.6.4. 
Follow-up Visit:  Week 10 (±3 days) or Early Termination ....................... 34 
9.7. 
Study Duration ............................................................................................. 34 
9.8. 
Prohibitions and Restrictions ....................................................................... 35 
9.8.1. 
Prior and Concomitant Medications ............................................................ 35 
9.8.2. 
Dietary Restrictions ..................................................................................... 35 
9.8.3. 
Other Restrictions ........................................................................................ 35 
9.9. 
Withdrawal Criteria ..................................................................................... 36 
9.9.1. 
Handling of Withdrawals ............................................................................. 36 
9.9.2. 
Sponsor’s Termination of Study .................................................................. 36 
10. 
STUDY DRUG ............................................................................................ 37 
10.1. 
Study Drug Supplies .................................................................................... 37 
10.2. 
Study Drug Storage ...................................................................................... 37 
10.3. 
Study Drug Packaging and Labeling ........................................................... 37 
10.4. 
Blinding ....................................................................................................... 38 
10.5. 
Study Drug Administration.......................................................................... 38 
10.6. 
Drug Compliance and Accountability ......................................................... 38 
10.7. 
Study Drug Return ....................................................................................... 38 
11. 
ADVERSE EVENTS................................................................................... 39 
11.1. 
Definition ..................................................................................................... 39 
11.2. 
Intensity of Adverse Events ......................................................................... 40 
11.3. 
Relationship to Study Drug ......................................................................... 40 
11.4. 
Recording Adverse Events .......................................................................... 40 
11.5. 
Post-Study Follow-Up of Adverse Events ................................................... 41 
11.6. 
Serious Adverse Events ............................................................................... 41 
11.6.1. 
Definition of a Serious Adverse Event ........................................................ 41 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 6


11.6.2. 
Managing Serious Adverse Events .............................................................. 42 
11.6.3. 
Reporting Serious Adverse Events and Other Immediately Reportable 
Events .......................................................................................................... 42 
11.6.4. 
Expedited Safety Reports ............................................................................ 42 
11.7. 
Pregnancy .................................................................................................... 43 
12. 
DOCUMENTATION OF DATA ................................................................ 43 
12.1. 
Case Report Form ........................................................................................ 43 
12.2. 
Data Capture, Review, and Validation ........................................................ 44 
12.3. 
Coding Dictionaries ..................................................................................... 44 
13. 
STATISTICAL AND ANALYTICAL PLAN ............................................ 44 
13.1. 
Analysis Sets ................................................................................................ 45 
13.2. 
Sample Size ................................................................................................. 45 
13.3. 
Handling of Missing Data ............................................................................ 45 
13.4. 
Enrollment and Disposition of Subjects ...................................................... 45 
13.5. 
Demographics and Baseline Characteristics ................................................ 45 
13.6. 
Study Drug Dosing and Compliance ........................................................... 46 
13.7. 
Pharmacokinetic Data .................................................................................. 46 
13.8. 
Efficacy Data ............................................................................................... 46 
13.9. 
Safety Data ................................................................................................... 47 
13.10. 
Software ....................................................................................................... 47 
13.11. 
Interim Analysis ........................................................................................... 47 
14. 
REGULATORY AND ETHICAL ISSUES ................................................ 47 
14.1. 
General Legal References ............................................................................ 47 
14.2. 
Institutional Review Board .......................................................................... 47 
14.3. 
Protocol Adherence and Amendments ........................................................ 47 
14.4. 
Required Documents ................................................................................... 48 
14.5. 
Informed Consent ........................................................................................ 48 
14.6. 
Study Monitoring ......................................................................................... 48 
14.7. 
Quality Assurance ........................................................................................ 49 
14.8. 
Record Retention ......................................................................................... 49 
14.9. 
Confidentiality ............................................................................................. 49 
15. 
STUDY COMMENCEMENT AND DISCONTINUATION ..................... 49 
16. 
REFERENCES ............................................................................................ 50 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 7


17.
APPENDICES ............................................................................................. 52
17.1. 
Yale Global Tic Severity Scale (YGTSS) ................................................... 52 
17.2. 
Rush Video-Based Tic Rating Scale (RTRS) .............................................. 62 
17.3. 
Premonitory Urge for Tics Scale (PUTS) .................................................... 64 
17.4. 
Clinical Global Impression of Tics (CGI-Tics)–Severity ............................ 66 
17.5. 
Clinical Global Impression of Change-Tourette Syndrome (CGI-TS)–
Improvement ................................................................................................ 68 
17.6. 
Columbia-Suicide Severity Rating Scale (C-SSRS) Baseline/Screening 
Version ......................................................................................................... 70 
17.7. 
Columbia-Suicide Severity Rating Scale (C-SSRS) Since Last Visit 
Version ......................................................................................................... 74 
17.8. 
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) ................................ 78 
17.9. 
Structured Interview Guide for the Hamilton Depression Rating Scale 17 
Item (SIGH-D-17) ....................................................................................... 93 
17.10. 
Extrapyramidal Symptom Rating Scale-Abbreviated ................................101 
LIST OF TABLES 
Table 1: 
Schedule of Assessments ............................................................................. 24 
Table 2: 
Estimated Total Blood Sample Volume ...................................................... 30 
Table 3: 
Intensity of Adverse Events ......................................................................... 40 
Table 4: 
Relationship of Adverse Events to Study Drug ........................................... 40 
LIST OF FIGURES 
Figure 1: 
Study Design Schematic .............................................................................. 19 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505
Clinical Study Protocol Amendment No. 3 Final Version
Confidential
29 June 2016
Page 8


2. 
SYNOPSIS 
Title of Study: 
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-
98854 in Adult Subjects with Tourette Syndrome 
Study centers: 
Approximately 40 study centers in the United States. 
Objectives: 
• 
To evaluate the efficacy of 2 active doses of NBI-98854 (40 mg and 80 mg) administered once daily 
in adult subjects with Tourette syndrome (TS). 
• 
To assess the safety and tolerability of repeated daily doses of NBI-98854 in adult subjects with TS. 
• 
To evaluate plasma exposure of NBI-98854 and its metabolite, NBI-98782, following repeated daily 
doses of NBI-98854. 
Study Design: 
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study in a 
total of 90 male and female subjects, 18 to 64 years of age, with a Diagnostic and Statistical Manual of 
Mental Disorders, 4th or 5th Editions (DSM-IV or -V) diagnosis of TS.   
After providing informed consent, subjects will be screened to determine eligibility within 21 days 
(Days -21 to -1) before the start of study drug dosing on Day 1.  On Day -1 (baseline), eligible subjects 
will return to the study center for collection of baseline safety and efficacy assessments and collection of 
a blood sample for subsequent determination of their cytochrome P450 2D6 (CYP2D6) metabolizer 
status.  Subjects who continue to be eligible for the study will then be randomized (1:1:1) to placebo or 
1 of 2 active doses of NBI-98854 (40 mg or 80 mg).  Study drug will be administered in a double-
dummy fashion throughout the 8-week double-blind treatment period.  Beginning on Day 1, study drug 
will be administered at home once daily in the morning with a standard breakfast through Week 8.  The 
NBI-98854 80 mg dose will be titrated in a blinded fashion (subjects will receive 40 mg for the first 
week followed by 80 mg for the remainder of the 8-week treatment period). 
At any time, if the subject is unable to tolerate their current dose, the investigator may decrease the 
subject’s dose.  The investigator is allowed to reduce the subject’s dose only one time during the study.  
Subjects who have had a dose reduction and are unable to tolerate their new dose will be discontinued 
from the study.  To maintain the study blind, subjects receiving 40 mg or placebo who have a dose 
reduction will continue to receive their current dose and subjects receiving 80 mg will be reduced to 
40 mg. 
During the double-blind treatment period, subjects will return to the study center at 2-week intervals 
(end of Weeks 2, 4, 6, and 8) for study assessments and dispensing of study drug (Weeks 2, 4, and 6 
only).  All subjects who have completed the 8-week treatment period will enter a 2-week follow-up 
period with a follow-up visit at Week 10 (or early termination).   
Efficacy, safety, and study drug exposure will be assessed at scheduled times throughout the study. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 9


Study Population: 
Approximately 90 male and female adult subjects between 18 and 64 years of age, with a DSM-IV or -V 
diagnosis of TS will be enrolled into this study.  The subjects must have at least moderate current TS 
symptomatology, as defined by a Clinical Global Impression of Tics (CGI-Tics)–Severity score of  
≥4 (ie, moderately ill) and a Yale Global Tic Severity Scale (YGTSS), Total Tic Severity Score of at 
least 20 points at screening.  In addition, subjects with Tourette spectrum diagnoses 
(eg, obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD], etc) must 
have a stable psychiatric status. 
Duration of treatment and study participation: 
The expected duration of study participation for each subject is approximately 13 weeks, including up to 
21 days of screening, an 8-week double-blind treatment period, and a 2-week drug-free follow-up 
period. 
Investigational product, dose, and mode of administration: 
NBI-98854 will be supplied as capsules containing 40 mg of NBI-98854 (free base).  The NBI-98854 
capsules will be taken with a standard breakfast.   
NBI-98854 will be administered in a double-dummy fashion.  Subjects randomized to receive 
NBI-98854 40 mg will receive one 40 mg capsule and one matching placebo capsule.  Subjects 
randomized to receive NBI-98854 80 mg will receive two 40 mg capsules (except during the first 7 days 
prior to dose titration when subjects will receive a 40 mg dose as one 40 mg capsule and one matching 
placebo capsule).  
Reference therapy, dose, and mode of administration 
Matching placebo capsules are identical in appearance and will be orally administered in a double-blind, 
double-dummy manner according to randomization on an identical schedule to those receiving 
NBI-98854.  The placebo capsules will be taken with a standard breakfast.  
Placebo will be administered in a double-dummy fashion.  Subjects randomized to placebo will receive 
two matching placebo capsules. 
Criteria for evaluation:   
Efficacy: 
The following efficacy assessments will be administered at screening, baseline (Day -1), Weeks 2, 4, 6, 
and 8, and at the follow-up visit (Week 10 or early termination): 
• 
Yale Global Tic Severity Scale (YGTSS; primary assessment) 
• 
Rush Video-based Tic Rating Scale (RTRS)  
• 
Premonitory Urge for Tics Scale (PUTS) 
• 
Clinical Global Impression of Change-Tourette Syndrome (CGI-TS)-Improvement 
• 
Clinical Global Impression of Tics (CGI-Tics)-Severity 
The CGI-Tics-Severity scale will be used to rate the Investigator’s assessment of the severity of tic 
symptoms at screening and baseline.  Both the CGI-Tics-Severity and CGI-TS-Improvement scales will 
be assessed by the investigator at Weeks 2, 4, 6, and 8; and at the follow-up visit (Week 10 or early 
termination). 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 10


Safety: 
Safety and tolerability will be monitored throughout the study and will include the following 
assessments:  
• 
Adverse events 
• 
Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) 
• 
Serum prolactin 
• 
Vital signs (including orthostatic blood pressures and pulse) 
• 
Physical examinations 
• 
12-lead electrocardiograms 
• 
Columbia Suicide Severity Rating Scale (C-SSRS) 
• 
Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) 
• 
Structured Interview Guide for the Hamilton Depression Rating Scale, 17-Item (SIGH-D-17) 
• 
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) 
Pharmacokinetics 
Blood samples to evaluate plasma concentrations of NBI-98854, and the metabolite NBI-98782 will be 
collected during the treatment period (end of Weeks 2, 4, 6, and 8) and at the follow-up visit (Week 10 
or at early termination). 
Statistical methods: 
The primary efficacy endpoint is the change from baseline (Day -1) to Week 8 in the YGTSS Total Tic 
Score (TTS).  Secondary efficacy endpoints include the YGTSS Global Tic Severity score mean change 
from baseline to Week 8, the RTRS total score mean change from baseline to Week 8; the PUTS total 
score mean change from baseline to Week 8, the CGI-TS-Improvement mean score change from 
baseline to Week 8, and the CGI-Tics-Severity score mean change from baseline to Week 8. 
Statistical comparisons between each NBI-98854 treatment group and placebo will be performed for the 
efficacy endpoints.  The primary analysis of the TTS change from baseline will be a mixed-effect model 
repeated measures (MMRM) analysis including the scores at Weeks 2, 4, 6, and 8 based on the 
per-protocol and intent-to-treat analysis sets.  Similar methods of analysis will be used for the secondary 
efficacy endpoints. 
Safety and plasma drug and metabolite concentration data will be summarized by treatment and 
timepoint using descriptive statistics. 
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 11


3. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
ADHD 
Attention-Deficit Hyperactivity Disorder 
AE 
Adverse event 
AIMS 
Abnormal Involuntary Movement Scale 
ALT 
Alanine transaminase 
AST 
Aspartate transaminase 
β-hCG 
β-human chorionic gonadotropin 
CBIT 
Comprehensive Behavioral Intervention for Tics 
CDS 
Clinical Drug Safety 
CFR 
Code of Federal Regulations 
CGI-TS 
Clinical Global Impression of Change-Tourette Syndrome 
CGI-Tics 
Clinical Global Impression of Tics  
Cmax 
Maximum plasma concentration 
CRT 
Controlled room temperature 
C-SSRS 
Columbia Suicide Severity Rating Scale 
CYP 
Cytochrome P450 
DSM-IV or -V 
Diagnostic and Statistical Manual of Mental Disorders 4th 
or 5th Editions 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
EDC 
Electronic data capture 
EDTA K2 
Dipotassium ethylenediaminetetraacetic acid 
ESRS-A 
Extrapyramidal Symptom Rating Scale-Abbreviated 
FDA 
[United States] Food and Drug Administration 
GCP 
Good Clinical Practices 
GGT 
Gamma-glutamyl transferase 
HBsAg 
Hepatitis B surface antigen 
HCV-Ab 
Hepatitis C virus antibody 
HIV-Ab 
Human immunodeficiency virus antibody 
ICF 
Informed consent form 
IRB 
Institutional Review Board 
ITT 
Intent-to-treat 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 12


IWRS 
Interactive Web Response System 
MAOI 
Monoamine oxidase inhibitor 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMRM 
Mixed-effects model repeated measures 
NBI 
Neurocrine Biosciences, Inc. 
NOAEL 
No observed adverse effect level 
PK 
Pharmacokinetic(s) 
PP 
Per-protocol 
PUTS 
Premonitory Urge for Tics Scale 
QTcF 
Corrected QT interval using Fridericia’s formula 
RTRS 
Rush Video-based Tic Rating Scale 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SD 
Standard deviation 
SIGH-D-17 
Structured Interview Guide for the Hamilton Depression 
Rating Scale, 17-Item 
TD 
Tardive dyskinesia 
TEAE 
Treatment-emergent adverse event 
TS 
Tourette syndrome 
TTS 
Total Tic Score 
ULN 
Upper limit of normal 
US 
United States 
VMAT2 
Vesicular monoamine transporter 2 
WBC 
White blood cell 
Y-BOCS 
Yale-Brown Obsessive-Compulsive Scale 
YGTSS 
Yale Global Tic Severity Scale 
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 13


4. 
ETHICS 
The study will be conducted in accordance with Neurocrine Biosciences, Inc. (NBI) standards 
that meet regulations relating to Good Clinical Practices (GCP).  These standards respect the 
following guidelines: 
• Good Clinical Practice: Consolidated Guideline (International Conference on 
Harmonization of Technical Requirements for the Registration of Pharmaceuticals for 
Human Use, May 1996). 
• United States (US) Code of Federal Regulations (CFR) dealing with clinical studies 
(21 CFR parts 50, 54, 56, 312, and 314). 
The ethical requirements of Institutional Review Boards/Ethics Committees (IRBs/ECs) and the 
Informed Consent Forms (ICFs) are discussed in Section 14. 
5. 
INTRODUCTION 
5.1. 
Background 
Tourette Syndrome (TS) is a movement disorder characterized by the presence of chronic motor 
and one or more vocal tics that often appear in childhood or early adolescence (APA DSM-IV, 
1994; APA DSM-V, 2013).  Tics are defined as rapid, non-rhythmic, stereotyped motor 
movements or vocalizations, and are typically categorized as simple or complex based on their 
overt features.  Simple tics are brief, meaningless actions (eg, forceful blinking of the eyes or 
grunting) and complex tics are slower, more purposeful behaviors (eg, gyrating or uttering 
phrases; Leckman et al., 1989; Cavanna and Nani, 2013; Shprecher and Kurlan, 2009).  The tics 
follow a waxing and waning course over time, and must be recurrent for a period of more than 
1 year to qualify for diagnosis.  In addition to tic phenomena, TS may also present with a 
constellation of symptoms that are part of a broader “TS spectrum,” which can include 
obsessive-compulsive behaviors, attention-deficit/hyperactivity disorder, and impulsive or 
antisocial behavior (Chen et al., 2012; Felling and Singer, 2011). 
It has been well established that TS is predominantly a disorder of childhood with a mean or 
median age of onset of approximately 6 years of age (Leckman et al., 1998; Robertson, 2011; 
Jankovic and Kurlan, 2011; Swain et al., 2007).  Tic symptomatology usually becomes the most 
severe around age 10 and by the time adulthood is achieved at 18 years of age, the majority of 
patients are either tic-free or their symptoms have significantly improved (Leckman et al., 1998; 
Kurlan, 2010).  TS symptoms may also occur in adults and these tic phenomena appear to be a 
re-emergence or an exacerbation of childhood onset TS (Chouinard and Ford, 2000; Jankovic 
and Kurlan, 2011). 
Persistent tics can have a significant impact on patient quality of life and often lead to impaired 
psychosocial functioning.  Some of these problems include social isolation, bullying, physical 
discomfort (with pain or injury), and poor academic and/or work performance (Roessner et al., 
2013).  Psychosocial stressors can, in turn, exacerbate tic symptomatology.  It is under these 
conditions that pharmacological interventions are often considered (Chen et al., 2012; 
Shprecher & Kurlan, 2009; Roessner et al., 2013). 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 14


Neuropathological models have been proposed to explain the symptomatic features of TS, and 
converging lines of empirical evidence consistently implicate dopaminergic dysfunction and 
dysregulation within prefrontal cortex-basal ganglia circuitry (Felling and Singer, 2011; 
Pourfar et al., 2011).  Functional neuroimaging studies have identified a pattern of prefrontal 
cortex hypermetabolism and reduced striatal activity in TS patients (Baxter and Guze, 1993; 
Braun et al., 1993; Pourfar et al., 2011).  Pharmacotherapeutic approaches aimed at blocking 
postsynaptic dopamine-2 receptors (eg, haloperidol and pimozide) have demonstrated efficacy 
in reducing TS symptoms.  In this regard, modulation of dopaminergic tone through the 
administration of a Vesicular monoamine transporter 2 (VMAT2) inhibitor, like NBI-98854, 
may also be an effective treatment option for tic suppression. 
Currently the only approved agent with VMAT2 inhibitory activity is tetrabenazine, a 
dopamine-depleting agent recently approved for the treatment of chorea associated with 
Huntington’s disease.  Use of tetrabenazine for the treatment of a variety of hyperkinetic 
movement disorders has also been described (Ondo et al, 1999; Jankovic and Beach, 1997).  
The beneficial pharmacologic effects of tetrabenazine on the targeted hyperkinetic involuntary 
movements have been documented, as well as the adverse effects associated with excessive 
monoamine depletion, such as sedation, depression, akathisia and parkinsonism.  The 
occurrence of these adverse effects with tetrabenazine have resulted in the need for 
individualized dosing, dose titration, and management of treatment-related side effects. 
5.2. 
NBI-98854 
NBI-98854 is an orally active valine ester of a VMAT2 inhibitor (NBI-98782) and is currently 
under development at NBI for the treatment of neuroleptic-induced Tardive dyskinesia (TD), 
TS, and other involuntary movement disorders.  Metabolism of NBI-98854 is characterized by 
conversion of NBI-98854 to NBI-98782, and cytochrome P450 (CYP) 3A4/5 dependent 
mono-oxidation to NBI-136110.  All three entities, namely, NBI-98854, NBI-98782 and 
NBI-136110, have the ability to bind to and inhibit VMAT2.  However, NBI-98782 is the most 
potent and appears to be responsible for the majority of the observed pharmacological activity 
of VMAT2 inhibition.   
The intravenous and oral NBI-98854 pharmacokinetics (PK) has been studied in mice, rats, 
monkeys, dogs, and humans.  In animals, orally administered NBI-98854 is rapidly absorbed 
and relatively slowly converted to NBI-98782, such that animals are exposed to both 
NBI-98854 and NBI-98782.  Dose-dependent increases in exposure to both NBI-98854 and 
NBI-98782 were seen in animal studies.  NBI-98854 appears to cause little or no CYP enzyme 
inhibition or induction at pharmacologically relevant concentrations.  The elimination of 
NBI-98782 is in part catalyzed by CYP2D6.  Repeat-dose nonclinical toxicology studies 
conducted in mice, rats, and dogs (up to 9 months duration) have revealed no adverse effects at 
doses of 60 mg/kg/day in the mouse, 3 mg/kg/day in the rat, and 15 mg/kg/day in the dog.  
Radiolabeled absorption, metabolism, distribution, and excretion studies have confirmed that all 
abundant human circulating metabolites were identified as circulating metabolites in both rat 
and dog providing justification for the use of these species for pivotal toxicology studies in the 
safety assessment of NBI-98854.  Additionally, cardiovascular, pulmonary, and CNS safety 
pharmacology studies have also been conducted, where the no observed adverse effect level 
(NOAEL) was equal to or exceeded the 15 mg/kg level seen in repeat-dose toxicology studies.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 15


NBI-98854 had a modest negative effect on rat fertility at 10 mg/kg/day (NOAEL of 
3 mg/kg/day).  The NOAEL for embryo/fetal development in rats and rabbits was 15 mg/kg/day 
and 50 mg/kg/day, respectively.  There was no evidence of teratogenicity in the rat or rabbits.  
Finally, NBI-98854 was negative in in vitro mutagenicity assays (namely, Ames and 
chromosomal aberration) and an in vivo rat micronucleus test. 
Twelve clinical studies with NBI-98854 have been completed to date; 8 Phase 1 studies in 
healthy subjects and subjects with hepatic impairment, and 4 Phase 2 studies in subjects with 
TD and a clinical diagnosis of schizophrenia or schizoaffective disorder, mood disorder, or 
gastrointestinal disorder.  The Phase 1 studies have evaluated the PK of NBI-98854 
administered as an oral solution or capsule formulation, PK assessments including serum 
prolactin and cognitive performance, and safety measures including evaluation of 
cardiovascular risk using triplicate 12-lead electrocardiogram (ECG) and 24-hour Holter 
monitoring.  The Phase 2 studies have included an evaluation of efficacy in the treatment of 
symptoms of TD using the Abnormal Involuntary Movement Scale (AIMS). 
Clinical PK data indicate that when administered orally under fasted conditions, NBI-98854 
appeared to be rapidly absorbed with maximum plasma concentration being reached within 
1 hour.  The metabolite NBI-98782 was formed gradually with maximum plasma concentration 
being reached 4 to 10 hours postdose.  Plasma concentrations for both NBI-98854 and 
NBI-98782 appeared to decline after reaching maximal concentration and both exhibited an 
apparent terminal half-life of approximately 20 hours in non-elderly adult subjects and 23 to 
28 hours in elderly subjects.  Preliminary data from healthy volunteer studies suggest that 
coadministration of NBI-98854 with strong CYP3A4 or CYP2D6 inhibitors is expected to 
increase the maximum plasma concentration (Cmax) and area under the plasma concentration 
versus time curve (AUC) of NBI-98782 by approximately 2-fold.  A similar approximately 
2-fold increase in NBI-98782 was observed when NBI-98854 was given to subjects with 
moderate or severe hepatic impairment. 
Results from Phase 2 studies indicated an improvement in the AIMS score after 6 weeks of 
continuous dosing with either NBI-98854 50 mg once daily, continuous dosing at NBI-98854 
100 mg once daily for 2 weeks followed by continuous dosing at NBI-98854 50 mg once daily 
for 4 weeks (NBI-98854-1201), or 6 weeks of titrated doses from 25 mg up to 75 mg 
NBI-98854 once daily (NBI-98854-1202).  Results from an open-label safety extension with 
dosing out to 12 weeks (NBI-98854-1201) continued to show benefit in subjects continuing on 
with 50 mg NBI-98854 daily dosing and also in subjects originally assigned to placebo who 
went on to receive 50 mg NBI-98854 for the 6 weeks of open-label treatment period.  Results 
from the 6-week dose-titration study (NBI-98854-1202) showed a statistically significant 
reduction in AIMS dyskinesia total score in the NBI-98854 group compared to placebo.  A 
statistically significant higher responder rate (ie, ≥50% improvement in AIMS dyskinesia total 
score from baseline) was also observed in the NBI-98854 group compared with placebo. 
NBI-98854 has been generally well tolerated in single doses up to 300 mg and in multiple doses 
of up to 100 mg.  Treatment-emergent adverse events (TEAEs) consistent with the 
pharmacological effects of monoamine reduction (eg, fatigue, insomnia, nervousness) occurred 
at a lower incidence in the NBI-98854 100 mg dose compared to the 50 mg dose in Phase 2 
studies.  Most TEAEs were transient and considered mild or moderate in intensity.  Thirteen 
treatment-emergent serious adverse events (SAEs) among 10 subjects have been reported.  No 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 16


SAEs have been assessed by the investigator as possibly related to study drug.  No 
cardiovascular, laboratory, or vital sign-related safety signals have been identified.  Increases in 
serum prolactin above normal laboratory ranges have been noted, but there have been no 
TEAEs associated with hyperprolactinemia.  In general, depression, drug-induced akathisia and 
drug induced parkinsonism did not worsen during treatment with NBI-98854. 
5.3. 
Study and Dose Rationale 
The present study is a Phase 2, randomized, double-blind, placebo-controlled, parallel 
fixed-dose study to evaluate the efficacy, safety and tolerability of 2 doses of NBI-98854 
(40 mg and 80 mg) for the treatment of TS.  Medically stable adult subjects with a diagnosis of 
DSM-IV or -V of TS will be randomized in a 1:1:1 ratio to self-administer placebo, NBI-98854 
40 mg, or NBI-98854 80 mg (approximately n=30 per treatment group) once daily for 8 weeks.  
Subjects will be required to have at least moderate TS as determined by the Yale Global Tic 
Severity Scale (YGTSS) and the CGI-Tics-Severity scale. 
Clinical data from subjects with the hyperkinetic movement disorder, TD, who were 
administered doses  of 12.5 mg to 100 mg per day in Phase 2 trials indicate that NBI-98854 is 
generally well tolerated and associated with dose-related efficacy in this disorder.  
Exposure-response modeling of the Phase 2 data in TD patients indicates that a steady state Cmax 
of 20 to 40 ng/mL NBI-98782 is an appropriate plasma concentration range for 
pharmacodynamic response.  Following consultation with the FDA Division of Psychiatry 
Products, the 40 mg and 80 mg doses of NBI-98854 were selected for evaluation in the Phase 3 
TD program.  It is anticipated that these same doses in the current study of adult TS subjects 
will provide the same exposure levels of NBI-98854 previously observed in the clinic, and will 
be associated with acceptable tolerability and robust efficacy, and will also allow for the drug to 
be administered regardless of CYP2D6 genotype or concomitant medication status.  In the TD 
patient population, doses below 40 mg are well tolerated but below the minimal effective dose, 
and doses above 80 mg afforded minor incremental benefit, but at an increased risk of adverse 
events (AEs). 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 17


6. 
STUDY OBJECTIVES 
The objectives of this clinical study are as follows: 
• To evaluate the efficacy of 2 active doses of NBI-98854 (40 mg and 80 mg) administered 
once daily in adult subjects with TS. 
• To assess the safety and tolerability of repeated daily doses of NBI-98854 in adult subjects 
with TS. 
• To evaluate plasma exposure of NBI-98854 and its metabolite, NBI-98782, following 
repeated daily doses of NBI-98854. 
7. 
OVERVIEW OF STUDY DESIGN 
7.1. 
Study Design 
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group 
study in a total of 90 male and female subjects, 18 to 64 years of age, with a Diagnostic and 
Statistical Manual of Mental Disorders, 4th or 5th Editions (DSM-IV or V) diagnosis of TS.   
After providing informed consent, subjects will be screened to determine eligibility within 
21 days (Days -21 to -1) before the start of study drug dosing on Day 1.  Subjects may also be 
asked to sign an optional release form to allow their Rush Video-based Tic Rating Scale 
(RTRS) video recordings to be used for educational purposes.   
On Day -1 (baseline), eligible subjects will return to the study center for collection of baseline 
safety and efficacy assessments and collection of a blood sample for subsequent determination 
of their cytochrome P450 2D6 (CYP2D6) metabolizer status.  Subjects who continue to be 
eligible for the study will then be randomized (1:1:1) to placebo or 1 of 2 active doses of 
NBI-98854 (40 mg or 80 mg).  A 2-week supply of study drug will be dispensed.  Study drug 
will be administered in a double-dummy fashion throughout the 8-week double-blind treatment 
period.  Beginning on Day 1, study drug will be administered at home once daily in the morning 
with a standard breakfast through Week 8.  The NBI-98854 80 mg dose will be titrated in a 
blinded fashion (subjects will receive 40 mg for the first week followed by 80 mg). 
At any time, if the subject is unable to tolerate their current dose, the investigator may decrease 
the subject’s dose.  The investigator is allowed to reduce the subject’s dose only one time 
during the study.  Subjects who have had a dose reduction and are unable to tolerate the new 
dose will be discontinued from the study.  To maintain the study blind, subjects receiving 40 mg 
or placebo who have a dose reduction will continue to receive their current dose and subjects 
receiving 80 mg will be reduced to 40 mg. 
During the double-blind treatment period, subjects will return to the study center at 2-week 
intervals (end of Weeks 2, 4, 6, and 8) for study assessments and dispensing of study drug 
(Weeks 2, 4, and 6 only).  All subjects who have completed the 8-week treatment period will 
enter a 2-week follow-up period with a follow-up visit at Week 10 (or early termination).   
Efficacy assessments for TS symptomatology will be performed using the YGTSS (primary), 
the RTRS, the Premonitory Urge for Tics Scale (PUTS), the Clinical Global Impression of 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 18


Change-Tourette Syndrome (CGI-TS)-Improvement scale, and the Clinical Global Impression 
of Tics (CGI-Tics)-Severity scale.  The YGTSS, RTRS, and PUTS will be administered at 
screening, on Day -1 (the day before dosing), during the double-blind treatment period (Weeks 
2, 4, 6, and 8), and at the follow-up visit (Week 10 or early termination).   
The CGI-Tics-Severity will be evaluated at screening and Day -1 (baseline), and then both 
CGI-Tics-Severity and CGI-TS-Improvement scales will be administered at Weeks 2, 4, 6, and 
8; and at the follow-up visit (Week 10 or early termination). 
Safety assessments will also be collected at scheduled times throughout the study including AE 
monitoring, clinical laboratory tests (hematology, serum chemistry, and urinalysis), vital sign 
measurements, physical examinations, ECGs, Columbia Suicide Severity Rating Scale 
(C-SSRS), Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A), Structured Interview 
Guide for the Hamilton Depression Rating Scale, 17-Item (SIGH-D-17), and the Yale-Brown 
Obsessive-Compulsive Scale (Y-BOCS). 
Blood samples for plasma drug concentration and metabolite analyses will be collected during 
the treatment period (end of Weeks 2, 4, 6, and 8), and on the follow-up visit (Week 10 or early 
termination). 
A schematic of the study design is shown in Figure 1. 
 
Figure 1: 
Study Design Schematic 
Week
-3
Screening
Randomized, Double-Blind, Placebo-Controlled
Treatment Period
6
Randomization on
Day -1
Screening
Period
2
4
Placebo
8
Follow-up
Follow-up /
Early Term.
NBI-98854 40 mg
NBI-98854 80 mg
10
 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 19


8. 
STUDY POPULATION 
This study will be conducted in approximately 90 male and female adult subjects with a 
DSM-IV or -V diagnosis of TS.  Subjects must meet all of the inclusion criteria and none of the 
exclusion criteria to enter the study. 
8.1. 
Inclusion Criteria 
To participate in this study, subjects must meet the following criteria: 
1. 
Have documentation of written informed consent. 
2. 
Be male or female, aged 18 to 64 years, inclusive. 
3. 
Be in good general health, as determined by medical history, physical examination, clinical 
laboratory assessments, and 12-lead ECG. 
4. 
Have a DSM-IV or -V diagnosis of TS. 
5. 
Have at least moderate current tic severity, as defined by a CGI-Tics-Severity score of ≥4 
(ie, moderately ill) and a YGTSS Total Tic Score (TTS) of ≥20 at screening.  This 
determination must be independently confirmed by the blinded external video reviewer 
using a video recording of the subject’s YGTSS assessment administered at the clinical site 
by the investigator (or designee). 
6. 
Have TS symptoms that impair school, occupational, and/or social function. 
7. 
Subjects with TS spectrum diagnoses (eg, obsessive-compulsive disorder [OCD], 
Attention-Deficit Hyperactivity Disorder [ADHD]) must have a stable psychiatric status as 
clinically determined by the investigator at screening and baseline.  
8. 
If medications are being used to treat TS symptoms and/or TS spectrum diagnoses, subjects 
must be on stable doses of these medications for a minimum of 30 days before baseline 
(Day -1), and the medication regimen is expected to remain stable throughout the study 
period.  The use of dopamine antagonists (eg, pimozide, haloperidol, aripiprazole, 
risperidone, clozapine, olanzapine, ziprasidone) and/or tetrabenazine to treat TS symptoms 
is prohibited.  Other non-dopaminergic tic suppression therapy (eg, clonidine, guanfacine) 
is allowed during the study period as long as the dose regimen has been stable for a 
minimum of 30 days before baseline (Day -1). 
9. 
Subjects with stable medical conditions requiring medications that are not prohibited per 
protocol must be on stable doses of these medications for a minimum of 30 days before 
baseline (Day -1), and the medication regimen is expected to remain stable throughout the 
study period. 
10. Subjects of childbearing potential who do not practice total abstinence must be instructed 
on the proper use of barrier methods of contraception and agree to use hormonal 
contraception or two forms of nonhormonal contraception (dual contraception) consistently 
from screening until 30 days after the last dose of study drug.   
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 20


Acceptable methods of contraception include the following: 
• Condom with spermicide (cream, spray, foam, gel, suppository, or polymer film). 
• Diaphragm with spermicide (with or without condom). 
• Cervical cap with spermicide (with or without condom). 
• Vaginal sponge impregnated with spermicide used with condom. 
• Intrauterine device (IUD). 
• Hormonal contraception taken for at least 3 months prior to screening. 
The following subjects are not required to use contraception: 
• Subjects who practice total abstinence from sexual intercourse as the preferred 
lifestyle are not required to use contraception (periodic abstinence is not acceptable). 
• Female subjects with partners or male subjects who had been vasectomized at least 
3 months prior to screening. 
• Female subjects who have been postmenopausal for at least 1 year prior to screening. 
• Female subjects who are surgically sterile (ie, bilateral oophorectomy, hysterectomy 
or bilateral tubal ligation) at least 3 months prior to screening. 
11. Female subjects of childbearing potential must have a negative serum β-human chorionic 
gonadotropin (β-hCG) pregnancy test at screening and negative urine pregnancy test at 
baseline (Day -1). 
12. Have a body mass index (BMI) of 18 to 40 kg/m2 (inclusive) at screening.  (BMI is defined 
as the subject’s weight in kg divided by the square of the subject’s height in meters.) 
13. Subjects must have a negative urine drug screen (negative for amphetamines, barbiturates, 
benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and baseline 
(Day -1).  Subjects who are on stable doses of prescribed and supervised (not prn) 
benzodiazepines, opiates, or psychostimulants (for subjects with comorbid ADHD) are 
allowed to participate in the study.  Subjects with a positive urine drug screen for 
cannabinoids are eligible for participation if the use is for medicinal purposes and there is 
no indication of cannabinoid abuse. 
14. Subjects must have a negative alcohol breath test at screening and baseline (Day -1). 
15. Be willing to provide authorization for access to personal health information in conjunction 
with US Health Insurance Portability and Accountability Act (HIPAA). 
16. Be willing and able to adhere to the study regimen and study procedures described in the 
protocol and informed consent forms, including all requirements at the study center and 
return for the final study day. 
8.2. 
Exclusion Criteria 
Subjects will be excluded from the study if they: 
1. 
Have an unstable medical condition or chronic disease (including history of neurological, 
hepatic, renal, cardiovascular, gastrointestinal, pulmonary, or endocrine disease), or 
malignancy that could confound interpretation of study outcome. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 21


2. 
Had a medically significant illness within 30 days of screening. 
3. 
Excessive use of tobacco and/or nicotine-containing products (based on the investigator’s 
assessment) within 30 days of screening. 
4. 
Have a history of substance (drug) dependence or abuse within the 3 months before 
baseline (Day -1), as defined in the DSM-IV (Substance Dependence or Abuse) or DSM-V 
(Substance Use Disorder).  
5. 
Are currently pregnant or lactating.  
6. 
Have a known history of neuroleptic malignant syndrome. 
7. 
Have a known history of long QT syndrome or cardiac arrhythmia. 
8. 
Have a screening or Day -1 average triplicate ECG QT interval corrected for heart rate 
using corrected QT interval using Fridericia’s formula (QTcF) of >450 msec (males) or 
>470 msec (females) or the presence of any clinically significant cardiac abnormality. 
9. 
Have any of the following laboratory test abnormalities at screening: 
• Serum creatinine >1.5 times the upper limit of normal (ULN). 
• Aspartate transaminase (AST) ≥2.5 times ULN. 
• Alanine transaminase (ALT) ≥2.5 times ULN. 
• Gamma-glutamyl transferase (GGT) ≥3.0 times ULN.  
• Total bilirubin >1.5 mg/dL. 
10. Have any of the following hematologic abnormalities at screening: 
• Hemoglobin <10.0 g/dL. 
• White blood cell (WBC) count <3.0 x 103/mm3. 
• Platelet count <100,000/mm3. 
11. Have a hematologic malignancy or solid tumor diagnosed within 3 years prior to screening, 
with the exception of localized skin cancer or carcinoma in situ of the cervix. 
12. Have biochemistry or hematology not within the laboratory’s reference range and deemed 
by the investigator to be clinically significant at screening. 
13. Have a positive human immunodeficiency virus antibody (HIV-Ab) test result, hepatitis B 
surface antigen (HBsAg) test result or hepatitis C virus antibody (HCV-Ab) test result at 
screening. 
14. Have received an investigational drug within 30 days before screening or plan to use an 
investigational drug (other than NBI-98854) during the study.   
15. Receive any excluded concomitant medication (refer to Section 9.8.1).   
16. Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the 
screening period or at baseline (Day -1) or plan to initiate CBIT during the study. 
17. Have a blood loss ≥550 mL or donated blood within 30 days before baseline (Day -1). 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 22


18. Have a significant risk of suicidal or violent behavior.  Subjects with any suicidal behavior 
or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without 
specific plan) or type 5 (active suicidal ideation with specific plan and intent) within the 
past year before screening based on the Columbia Suicide Severity Rating Scale (C-SSRS) 
should be excluded. 
19. Have ingested foods containing poppy seeds within 7 days before screening and baseline 
(Day -1). 
20. Have an allergy, hypersensitivity, or intolerance to tetrabenazine. 
21. Have a history of or suspected poor compliance in clinical research studies. 
8.3. 
Subject Identification and Replacement 
Subjects will be identified by their unique subject number and initials (first, middle, last).  The 
subject initials and subject number will be noted on electronic case report forms (eCRFs), all 
source documentation, laboratory documents, and ECG tracings.  Subjects who discontinue 
from the study will not be replaced. 
8.4. 
Randomization 
An Interactive Web Response System (IWRS) will be used to randomize subjects to 1 of 
3 double-blind treatment assignments during the 8-week double-blind treatment period:  
placebo or 1 of 2 active NBI-98854 doses (NBI-98854 40 mg or 80 mg) in a 1:1:1 ratio.  
Randomization will occur at baseline (Day -1) after the subject is confirmed to have met the 
eligibility criteria.  Treatment assignments will be made according to a computer-generated 
randomization schedule.  Investigators or a designee will access the IWRS to obtain 
randomization assignments. 
9. 
STUDY EVALUATIONS 
9.1. 
Schedule of Assessments 
A schedule of assessments that summarizes the frequency and timing of all assessments is 
provided in Table 1.  No protocol related procedures should be performed before subjects 
provide written informed consent.  Subject related events and activities including specific 
instructions, procedures, concomitant medications, dispensing of study drug, and descriptions of 
AEs should be recorded in the appropriate source documents and eCRFs. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 23


Table 1: 
Schedule of Assessments 
Procedure 
Screening 
Period 
Baseline 
Double-Blind Placebo-Controlled 
Treatment Period 
Follow-up/ 
Early 
Term.a 
Week 
-3 to -1 
Day -1 
2b 
4b 
6b 
8b 
10b 
Visit 
1 
2 
3 
4 
5 
6 
7 
Informed consent 
X 
 
 
 
 
 
 
Inclusion/exclusion criteria 
X 
UPDATE 
 
 
 
 
 
Medical history 
X 
UPDATE 
 
 
 
 
 
Physical examination (including weight) 
X 
X 
X 
X 
X 
X 
X 
Height 
X 
 
 
 
 
 
 
Vital signs 
X 
X 
X 
X 
X 
X 
X 
12-lead ECGc 
X 
X 
X 
X 
X 
X 
X 
Pregnancy testd 
X (S) 
X (U) 
X (U) 
X (U) 
X (U) 
X (U) 
X (U) 
Serology (HBsAg, HCV-Ab and HIV-Ab) 
X 
 
 
 
 
 
 
Clinical laboratory testse 
X 
X 
X 
X 
X 
X 
X 
Urine drug screenf 
X 
X 
 
 
 
 
 
Alcohol breath test 
X 
X 
 
 
 
 
 
Genotype blood sample 
 
X 
 
 
 
 
 
Serum prolactin 
 
X 
X 
X 
X 
X 
X 
Plasma sample for NBI-98854 and metabolite 
concentrations 
 
 
X 
X 
X 
X 
X 
YGTSS (including video recording) 
X 
X 
X 
X 
X 
X 
X 
RTRS  
X 
X 
X 
X 
X 
X 
X 
PUTS 
X 
X 
X 
X 
X 
X 
X 
CGI-Tics – Severity 
X 
X 
X 
X 
X 
X 
X 
CGI-TS-Improvement 
 
 
X 
X 
X 
X 
X 
C-SSRS 
X 
X 
X 
X 
X 
X 
X 
ESRS-A 
 
X 
X 
X 
X 
X 
X 
Y-BOCS and SIGH-D-17 
X 
X 
X 
X 
X 
X 
X 
Randomization 
 
X 
 
 
 
 
 
Study drug dosing at homeg 
 
 
X 
X 
X 
X 
 
Dispense study drugh 
 
X 
X 
X 
X 
 
 
Study drug accountabilityi 
 
 
X 
X 
X 
X 
 
AE monitoring 
X 
X 
X 
X 
X 
X 
X 
Prior and concomitant medications 
X 
X 
X 
X 
X 
X 
X 
Outpatient clinic visits 
X 
X 
X 
X 
X 
X 
X 
AE=adverse event; CGI-Tics=Clinical Global Impression of Tics; CGI-TS=Clinical Global Impression of Change-Tourette 
Syndrome; C-SSRS=Columbia Suicide Severity Rating Scale; Y-BOCS=Yale-Brown Obsessive-Compulsive Scale; 
ECG=Electrocardiogram; ESRS-A=Extrapyramidal Symptom Rating Scale-Abbreviated; ET=early termination; SIGH-D-
17=Structured Interview Guide for the Hamilton Depression Rating Scale ; HBsAg=hepatitis B surface antigen; HCV-
Ab=hepatitis C virus antibody; HIV-Ab=human immnunodeficiency virus antibody; PUTS=Premonitory Urge for Tics Scale; 
RTRS=Rush Video-Based Tic Rating Scale; S=serum; U=urine; YGTSS=Yale Global Tic Severity Scale. 
a. Final study visit for subjects who complete the study (or early termination). 
b. Visit window of ±3 days. 
c. A standard 12-lead ECG will be conducted in triplicate (1 to 3 minutes apart) after the subject has rested supine for at least 
5 minutes.  The ECG parameters that will be assessed include HR, QTc, QTcF, and PR intervals, and QRS duration based on 
the ECG machine readings (QTcF may be calculated). 
d. A serum pregnancy test will be conducted at screening, and urine pregnancy tests will be conducted at all other study visits 
for female subjects of childbearing potential. 
e. Clinical laboratory tests include hematology, chemistry, and urinalysis.  All blood samples will be obtained under non-fasted 
conditions.  
f.  Urine drug screen will be analyzed by the central laboratory.  In addition, urine testing kits will be provided by the central 
laboratory to confirm negative drug screen on Day -1.  A urine drug screen using a kit provided by the central laboratory may 
be conducted at the clinical site at any time during the study if the subject is suspected of substance or drug abuse. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 24


g. Study drug will be taken once daily at home starting on Day 1 (in the morning at approximately the same time) throughout 
the double-blind treatment period. 
Footnotes continue on the next page. 
h. Study drug will be dispensed on Day -1 and at Weeks 2, 4, and 6.  The NBI-98854 80 mg dose will be titrated in a blinded 
fashion (subjects will receive 40 mg for the first week followed by 80 mg).  Subjects will record the date and time study drug 
was taken as indicated in the study drug kit. 
i. At Weeks 2, 4, 6, and 8 subjects will return all empty study drug packaging and unused study drug, and a compliance check 
will be performed by counting the capsules returned at each study visit. 
9.2. 
Screening and Baseline Assessments 
9.2.1. 
Genotyping 
On Day -1 (baseline), a blood sample will be collected from enrolled subjects for the analysis of 
CYP2D6 status (ie, extensive, intermediate, poor, or ultrarapid metabolizers).  Approximately 
4 mL of blood will be collected in tubes containing dipotassium ethylenediaminetetraacetic acid 
(EDTA K2).  After the sample is obtained, it should be thoroughly mixed.  The vials will be 
stoppered and labeled with the study barcode and subject number.  The samples will be stored at 
approximately -20°C within approximately 15 minutes of collection.  The collection and 
submission of medical information will be accomplished with strict adherence to professional 
standards of confidentiality.  Genotyping blood samples collected from subjects will be shipped 
to a central laboratory for analysis. 
9.3. 
Efficacy Assessments 
9.3.1. 
Yale Global Tic Severity Scale 
The YGTSS will serve as the primary assessment of tic behaviors associated with TS 
(Leckman et al., 1989).  The YGTSS is designed to rate the overall severity of motor and phonic 
tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and 
interference.  The scale also includes an impairment assessment.  The YGTSS will be 
administered by the investigator (or qualified designee) using a computer-based structured 
clinical interview.  At each timepoint, the YGTSS interview will be video recorded in its 
entirety.  The video recording will follow a standardized set of guidelines and the recorded 
video will be uploaded to a secure central server.  A blinded, external video reviewer will access 
the central server to view the recording and (1) confirm the subject’s TS severity as at least 
moderate (at screening only), and (2) determine if the YGTSS interview program was 
administered properly.  The computer software system for the YGTSS administration, Rater 
Station™ (Bracket Global LLC, Philadelphia, PA), will prompt the investigator (or a qualified 
designee), a trained and certified rater, to enter a score for each item of the scale based on 
subject responses during the structured clinical interview.  The software will also generate 
individual scores for each item of the scale (tandem rating) and will generate the TTS and the 
Global Tic Severity Score.  
The YGTSS will be administered at screening, baseline (Day -1), during the double-blind 
treatment period (Weeks 2, 4, 6, and 8), and at the follow-up visit (Week 10 or early 
termination).  A copy of the YGTSS is provided in Appendix 17.1. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 25


9.3.2. 
Rush Video-Based Tic Rating Scale 
A modified RTRS will be used in this study that includes short video recordings to measure 
5 tic variables: number of body areas affected, frequency of motor and phonic tics, and severity 
of motor and phonic tics (Goetz et al., 1999).  Subjects must be video recorded while seated 
comfortably in a quiet room facing the camera with their hands in their lap and feet on the floor.  
If desired, subjects may read a book, as long as these activities do not block the camera’s view 
of their face, neck and shoulders, arms, and legs.  Subjects should be video recorded for a total 
of approximately 10 minutes.  The investigator (or designee) should be present for 
approximately the first 2.5 minutes to aid the subject in adjusting to the procedure.  The subject 
should then be video recorded alone for approximately 5 minutes.  The investigator (or 
designee) should then re-enter the room and remain seated quietly in a corner of the room for 
approximately the last 2.5 minutes of the video recording.  The RTRS videos will be reviewed 
and scored by a blinded central rater using a triple-blind scoring process. 
The RTRS will be administered at screening, baseline (Day -1), during the double-blind 
treatment period (Weeks 2, 4, 6, and 8), and at the follow-up visit (Week 10 or early 
termination).  A copy of the modified RTRS is provided in Appendix 17.2. 
9.3.3. 
Premonitory Urge for Tics Scale 
The Premonitory Urge for Tics Scale (PUTS) is a valid and reliable instrument for quantifying 
the premonitory urge phenomena associated with tics (Woods et al., 2005).  Each of the 9 items 
in the PUTS is rated on a 4-point scale (1 = not at all true, 2 = a little true, 3 = pretty much true, 
4 = very much true) and summed to yield at a total score reflecting the presence and frequency 
of pre-tic (ie, premonitory) urges along with relief that may be experienced after tics have been 
completed.   
The investigator (or designee) will administer the PUTS at screening, baseline (Day -1), during 
the double-blind treatment period (Weeks 2, 4, 6, and 8), and at the follow-up visit (Week 10 or 
early termination).  A copy of the PUTS is provided in Appendix 17.3. 
9.3.4. 
Clinical Global Impression of Tourette Syndrome 
The CGI-Tics – Severity and CGI-TS – Improvement scales will be used to rate the subject’s 
overall severity and overall improvement of TS.   
The CGI-Tics-Severity scale will be used to assess overall severity on a 7-point scale (range; 
1=normal, not at all ill to 7=among the most extremely ill patients).  The CGI-Tics – Severity 
will be assessed by the investigator at screening, baseline (Day -1), Weeks 2, 4, 6, and 8 and at 
the follow-up visit (Week 10 or upon early termination).  A copy of the CGI-Tics – Severity 
scale is provided in Appendix 17.4. 
The CGI-TS – Improvement scale will be used to assess overall improvement since the 
initiation of study drug dosing on a 7-point scale (range; 1=very much improved to 7=very 
much worse).  CGI-TS-Improvement scales will be assessed by the investigator at Weeks 2, 4, 
6, and 8 and at the follow-up visit (Week 10 or upon early termination).  A copy of the 
CGI-TS-Improvement scale is provided in Appendix 17.5. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 26


9.4. 
Pharmacokinetic Evaluations 
Blood samples to evaluate plasma concentrations of NBI-98854 and the metabolite NBI-98782 
will be collected during the treatment period (end of Weeks 2, 4, 6, and 8) and the follow-up 
visit (Week 10 or early termination).  The exact time of collection will be recorded on the 
eCRF. 
For each plasma sample, approximately 2 mL of blood will be collected in tubes containing 
EDTA K2.  Once obtained, the samples should be thoroughly mixed.  If the sample is not 
centrifuged immediately, the collection tube will be placed upright in a test tube rack and kept 
on crushed ice.  Within 1 hour of collection, samples will be centrifuged at approximately 
2,000 g for 10 minutes, preferably under refrigerated conditions (2 to 8°C).  The separated 
plasma will be aspirated using a disposable pipette and then transferred in approximately equal 
volumes into two vials.  The vials will be stoppered and labeled with the study barcode, subject 
number, primary or back-up sample designation (PK A and PK B, respectively), and nominal 
study date.  The samples will be stored at approximately -20°C within approximately 
15 minutes of centrifugation.  The date and actual 24-hour clock time of each collection will be 
recorded on the eCRF.  The duplicate plasma sample at each timepoint will be stored and used 
as backup.  These samples (including a manifest with additional information) will be shipped to 
a central laboratory for analysis to be stored at approximately -70°C.  Plasma samples 
remaining at the end of the study may be used for exploratory assessments. 
9.5. 
Safety Assessments 
Concomitant medication use and AEs will be monitored throughout the study as described in 
Sections Section 9.8.1 and Section 11, respectively.  Additional safety assessments are 
described in the following sections. 
Any abnormal vital sign measurement, physical examination finding, clinical laboratory test, or 
ECG parameter deemed clinically significant by the investigator will be repeated, including test 
results obtained on the follow-up visit (Week 10) or at early termination, until the value returns 
to baseline (or within normal limits), or the investigator deems the abnormality to be of no 
clinical significance.  If the investigator determines that a subject has a clinically significant 
finding of treatment-emergent depression, suicidal ideation, psychiatric symptoms (based upon 
the C-SSRS, SIGH-D-17, Y-BOCS, or clinical assessment), the finding will be documented as 
an AE, and appropriate psychiatric evaluation and intervention will be provided. 
9.5.1. 
Vital Sign Measurements 
Vital signs will include orthostatic systolic and diastolic blood pressure, orthostatic pulse rate, 
respiratory rate (recorded only supine) and oral body temperature.  Blood pressure will be 
measured using a calibrated automatic blood pressure cuff after the subject has been supine for 
at least 5 minutes and after approximately 2 minutes of standing.  The automatic blood pressure 
cuff will also provide pulse rate measurement. 
Vital sign measurements will be collected at screening, Day -1, and Weeks 2, 4, 6, 8, and 10 
(or upon early termination). 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 27


9.5.2. 
Medical History 
A medical history will be taken at the screening visit and updated on Day -1.  The age at TS 
diagnosis will be documented for all subjects; if necessary, subject age at TS onset can be 
estimated by the investigator based upon available clinical information. 
9.5.3. 
Physical Examination, Including Height and Weight 
The complete physical examination will consist of an assessment of general appearance, skin 
and mucosae, head, eyes, ears, nose, throat, neck (including thyroid), lymph nodes, chest/lungs, 
cardiovascular, abdomen, extremities, musculoskeletal, and neurological system.  A complete 
physical examination including weight will be performed at screening, Day -1, and Weeks 2, 4, 
6, 8, and 10 (or upon early termination).  Height will be measured at screening only.  Height and 
weight will be measured with subjects not wearing shoes. 
9.5.4. 
Electrocardiogram 
A standard 12-lead ECG will be recorded in triplicate (1 to 3 minutes apart) after the subject has 
rested supine for at least 5 minutes.  The ECG parameters that will be assessed include heart 
rate (HR), PR interval, QRS duration, QTc interval, and QTcF (machine readings or calculated).  
Additionally, the occurrence of de- and re-polarization and rhythm disorders or other 
abnormalities will be assessed.  Based on the review of these parameters, the investigator or 
designee will note if the ECG is Normal, Abnormal not Clinically Significant, or Abnormal 
Clinically Significant.  If the ECG is Abnormal Clinically Significant, the investigator or 
designee will provide a description of the abnormality recorded on the AE eCRF. 
The 12-lead ECG recordings will be conducted at screening, Day -1, and Weeks 2, 4, 6, 8, and 
10 (or upon early termination). 
9.5.5. 
Clinical Laboratory Assessments 
All clinical laboratory assessments will be performed by a central laboratory, which will 
provide instructions and supplies to the study staff before study initiation.  The instructions will 
be included in a laboratory manual.  The laboratory test battery will include routine and 
screening laboratory tests.  Laboratory samples will be collected in the following approximate 
amounts:  4 mL for hematology and 5 mL for serum chemistry (includes screening serum 
pregnancy tests for female subjects of childbearing potential).   
Clinical safety laboratory assessments will be performed at screening, Day -1 (baseline), and 
Weeks 2, 4, 6, 8, and 10 (or upon early termination).  There are no fasting requirements for 
laboratory assessments. 
The following clinical safety laboratory assays will be performed: 
Hematology: complete blood count including WBC count with differential, red blood cell count, 
hemoglobin, hematocrit, platelet count, mean corpuscular hemoglobin (MCH), mean 
corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), red cell 
distribution width (RDW) and mean platelet volume (MPV). 
Clinical Chemistry: sodium, potassium, calcium, magnesium, chloride, blood urea nitrogen, 
bicarbonate, creatinine, uric acid, albumin, alkaline phosphatase, lactate dehydrogenase, ALT, 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 28


AST, GGT, creatine kinase, total bilirubin, total cholesterol, triglycerides, total protein and 
glucose. 
Urinalysis: specific gravity, nitrite, ketones, protein, urobilinogen, glucose, bilirubin, leukocyte 
esterase, occult blood, and pH; microscopic examination of sediment will be performed only if 
the results of the urinalysis dipstick evaluation are positive for glucose, protein, leukocyte 
esterase, or blood. 
The following additional laboratory tests will be performed: 
Serum Prolactin:  Blood samples to determine serum prolactin concentration will be collected at 
baseline (Day -1), at Weeks 2, 4, 6, and 8; and at the follow-up visit (Week 10 or upon early 
termination).  Approximately 5 mL of blood will be collected into a serum separator tube.  
Serum prolactin samples will be shipped to a central laboratory for analysis. 
Serology:  Blood will be collected for HIV-Ab, HBsAg, and Hepatitis C virus antibody 
(HCV-Ab) testing at screening (as part of clinical chemistry).  The results of the Anti-HIV-Ab 
testing will be retained by the study site under confidential restriction.  The following 
approximate amounts will be collected:  10 mL. 
Urine Drug Screen and Alcohol Breathalyzer Test:  The urine drug screen will test for 
amphetamines barbiturates, phencyclidine, benzodiazepines, cannabinoids, cocaine, and opiates.  
Urine testing kits will be provided by the central laboratory to confirm negative drug screen 
prior to dosing.  A separate urine sample will also be sent to the central laboratory for analysis.  
A urine drug screen and alcohol breathalyzer test will be performed at screening and on Day -1.  
Subjects with a positive urine drug screen for cannabinoids are eligible for participation if the 
use is for medicinal purposes and there is no indication of cannabinoid abuse.  A urine drug 
screen using a kit provided by the central laboratory may be conducted at the clinical site at any 
time during the study if the subject is suspected of substance or drug abuse. 
Pregnancy Tests:  A pregnancy test will be conducted for female subjects of childbearing 
potential.  A serum pregnancy test will be conducted at screening and a urine pregnancy test 
will be conducted on Day -1, Weeks 2, 4, 6, and 8, and at the follow-up visit (Week 10 or upon 
early termination). 
9.5.6. 
Columbia-Suicide Severity Rating Scale  
The C-SSRS is a validated instrument to prospectively assess suicidal ideation and behavior 
(http://www.cssrs.columbia.edu).  There are versions of the questionnaire designed for use at 
screening (Baseline/Screening version) and at baseline and visits throughout the study (Since 
Last Visit version).  All versions of the C-SSRS include a series of screening questions related 
to suicidal ideation and suicidal behavior.  Subject responses of ‘yes’ to one or more screening 
questions will prompt additional questions that evaluate frequency and intensity of suicidal 
ideation and/or behavior.  Subjects with any lifetime suicidal behavior or suicidal ideation of 
type 4 (active suicidal ideation with some intent to act, without specific plan) or type 5 (active 
suicidal ideation with specific plan and intent) in the 1 year before screening based on the 
C-SSRS should be excluded (see exclusion criterion #17 in Section 8.2). 
The C-SSRS will be administered and scored by the investigator or qualified study center 
personnel at screening, Day -1, and Weeks 2, 4, 6, 8, and 10 (or upon early termination).  
Copies of each of the C-SSRS versions are provided in Appendix 17.6 and Appendix 17.7. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 29


9.5.7. 
Extrapyramidal Symptom Rating Scale-Abbreviated 
The ESRS-A is a psychometrically validated instrument that assesses 4 types of movement 
disorders:  parkinsonism, akathisia, dystonia, and tardive dyskinesia (TD) (Chouinard and 
Margolese, 2005).  The investigator (or designee) will administer the ESRS-A at baseline 
(Day -1), during the treatment period (Weeks 2, 4, 6, and 8), and at the follow-up visit 
(Week 10 or upon early termination).  A copy of the ESRS-A is provided in 
Appendix 17.10.Yale-Brown Obsessive Compulsive Scale 
The Y-BOCS is a semistructured interview designed to rate the severity of obsessive and 
compulsive symptoms.  The investigator (or designee) will administer the Y-BOCS at 
screening, Day -1, and Weeks 2, 4, 6, 8, and 10 (or upon early termination).  A copy of the 
Y-BOCS is provided in Appendix 17.8. 
9.5.8. 
Structured Interview Guide for the Hamilton Depression Rating Scale  
The Hamilton Depression Rating Scale is one of the most commonly used scales for rating 
depression.  To standardize the administration of this scale, the Investigator (or designee) will 
use the SIGH-D-17.  This clinician-rated interview consists of 17 items.  Each item on the 
questionnaire is scored on a 3, 4, or 5-point scale and individual item scores are summed up to 
yield a total score.  The investigator (or designee) will administer the SIGH-D-17 at screening, 
Day -1, and Weeks 2, 4, 6, 8, and 10 (or upon early termination).  A copy of the SIGH-D-17 is 
provided in Appendix 17.9. 
9.5.9. 
Estimated Total Blood Sample Volume Required by Study 
The estimated total blood sample volume for each subject is presented in Table 2.  These 
estimates include samples to be collected during screening, the treatment periods, and at the 
follow-up visit (or early termination). 
Table 2: 
Estimated Total Blood Sample Volume 
Parameter 
Number of Samples 
Required 
Approximate 
Volume (mL) 
Approximate Total 
Volume (mL) 
Serum chemistrya 
7 
5 
35 
Hematology 
7 
4 
28 
Genotyping 
1 
4 
4 
Serology 
1 
10 
10 
Serum prolactin 
6 
5 
30 
Pharmacokinetics 
5 
2.5b 
12.5 
Approximate Maximum Total Blood Sample Volume per Subject (mL): 
119.5 
a Includes pregnancy test for female subjects who are of childbearing potential at screening. 
b Includes 0.5 mL of discard volume per sample. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 30


9.6. 
Specific Study Information 
After providing subject informed consent subjects will undergo screening procedures within 
21 days of Day -1.  Subjects may also be asked to sign an optional release form to allow their 
RTRS video recordings to be used for educational purposes. 
9.6.1. 
Screening (Days -21 to -2) 
During screening, the following study evaluations and tasks will be performed at the study 
center: 
• Obtain informed consent. 
• Assess inclusion/exclusion criteria. 
• Collect medical history. 
• Perform a physical examination (including height and weight). 
• Collect vital signs, including orthostatic systolic and diastolic blood pressures, orthostatic 
pulse rate, respiratory rate, and body temperature. 
• Perform 12-lead ECG in triplicate (1 to 3 minutes apart). 
• Perform a serum pregnancy test (β-hCG) only for female subjects of childbearing potential. 
• Collect blood sample for serology testing (HIV-Ab, HBsAg, and HCV-Ab). 
• Collect blood sample for hematology and clinical chemistry. 
• Collect urine sample for urinalysis. 
• Perform alcohol breathalyzer test and urine drug screen. 
• Administer the YGTSS, including video recording. 
• Video record subjects for the RTRS. 
• Administer the PUTS. 
• Administer the CGI-Tics – Severity scale. 
• Administer the C-SSRS (Screening/Baseline version). 
• Administer the Y-BOCS and SIGH-D-17. 
• AE monitoring. 
• Record prior medications. 
All screening procedures must be completed and results evaluated by the investigator before the 
baseline procedures are performed on Day -1. 
The following items will also be conducted at screening: 
• Instruct subjects of childbearing potential who do not practice total abstinence to continue 
using contraception (see inclusion criterion #10 in Section 8.1). 
• Eligible subjects will be instructed to return to the center on Day -1. 
9.6.2. 
Baseline (Day -1) 
Subjects will return to the center on Day -1. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 31


On Day -1, the following study evaluations and procedures will be performed at the study 
center: 
• Update subject’s eligibility. 
• Update medical history. 
• Perform a physical examination and weight. 
• Collect vital signs, including orthostatic systolic and diastolic blood pressures, orthostatic 
pulse rate, respiratory rate, and body temperature. 
• Perform 12-lead ECG in triplicate (1 to 3 minutes apart). 
• Perform a urine pregnancy test for female subjects of childbearing potential. 
• Collect blood sample for hematology and clinical chemistry. 
• Collect urine sample for urinalysis. 
• Perform alcohol breathalyzer test and urine drug screen. 
• Collect blood sample for CYP2D6 genotype status. 
• Collect blood sample for serum prolactin. 
• Administer the YGTSS, including video recording. 
• Video record subjects for the RTRS. 
• Administer the PUTS. 
• Administer the CGI-Tics – Severity scale 
• Administer the C-SSRS (Since Last Visit version). 
• Administer the ESRS-A. 
• Administer the Y-BOCS and SIGH-D-17. 
• Access the IWRS to obtain randomization assignments for eligible subjects. 
• Dispense a 2-week supply of study drug and provide instructions on storage and 
administration of the study drug.  Note:  The NBI-98854 80 mg dose will be titrated in a 
blinded fashion (subjects will receive 40 mg for the first week followed by 80 mg). 
• Instruct subjects to take study drug daily with a standard breakfast between 0700 and 
1000 hours throughout the double-blind treatment period.  (The timing of drug 
administration should remain consistent throughout the treatment period.) 
• Instruct subjects to record the date and time of each dose in the space provided on the study 
drug kit. 
• Instruct subjects to return to the study center at Week 2 (±3 days) and to return all empty 
study drug packaging and unused study drug. 
• AE monitoring. 
• Record concomitant medications. 
The following will also be conducted before subjects may leave the study center: 
• Instruct subjects of childbearing potential who do not practice total abstinence to continue 
using contraception (see inclusion criterion #10 in Section 8.1). 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 32


• Instruct subjects to notify the investigator by telephone if they experience any AEs and 
before taking any new concomitant medications. 
9.6.3. 
Treatment Period:  Weeks 2, 4, 6, and 8 (±3 days for each visit) 
Subjects will report to the study center at Weeks 2, 4, 6, and 8. 
At Weeks 2, 4, 6, and 8 the following study evaluations and procedures will be performed at the 
study center: 
• Perform a physical examination and weight. 
• Collect vital signs, including orthostatic systolic and diastolic blood pressures, orthostatic 
pulse rate, respiratory rate, and body temperature. 
• Perform 12-lead ECG in triplicate (1-3 minutes apart). 
• Perform a urine pregnancy test for female subjects of childbearing potential. 
• Collect blood sample for hematology and clinical chemistry.  
• Collect urine sample for urinalysis. 
• Collect blood sample for serum prolactin. 
• Collect PK blood sample for NBI-98854 and metabolite concentrations. 
• Administer the YGTSS, including video recording. 
• Video record subjects for the RTRS. 
• Administer the PUTS. 
• Administer the CGI-Tics–Severity scale 
• Administer the CGI-TS–Improvement scale. 
• Administer the C-SSRS (Since Last Visit version). 
• Administer the ESRS-A. 
• Administer the Y-BOCS and SIGH-D-17. 
• Dispense a 2-week supply of study drug (Weeks 2, 4, and 6 only). 
• Perform compliance check by counting the capsules returned. 
• AE monitoring. 
• Record concomitant medications. 
The following will also be conducted before subjects may leave the study center: 
• Instruct subjects of childbearing potential who do not practice total abstinence to continue 
using contraception (see inclusion criterion #10 in Section 8.1).   
• Instruct subjects to notify the investigator by telephone if they experience any AEs and 
before taking any new concomitant medications. 
At any time, if the subject is unable to tolerate their current dose, the investigator may decrease 
the subject’s dose.  The investigator is allowed to reduce the subject’s dose only one time 
during the study.  Subjects who have had a dose reduction and are unable to tolerate their new 
dose will be discontinued from the study.  To maintain the study blind, subjects receiving 40 mg 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 33


or placebo who have a dose reduction will continue to receive their current dose and subjects 
receiving 80 mg will be reduced to 40 mg. 
9.6.4. 
Follow-up Visit:  Week 10 (±3 days) or Early Termination 
At Week 10 (or upon early termination) the following procedures will be performed at the study 
center: 
• Perform a physical examination and weight. 
• Collect vital signs, including orthostatic systolic and diastolic blood pressures, orthostatic 
pulse rate, respiratory rate, and body temperature. 
• Perform 12-lead ECG in triplicate (1-3 minutes apart). 
• Perform a urine pregnancy test for female subjects of childbearing potential. 
• Collect blood sample for hematology and clinical chemistry.  
• Collect urine sample for urinalysis. 
• Collect blood sample for serum prolactin. 
• Collect PK blood sample for NBI-98854 and metabolite concentrations. 
• Administer the YGTSS including video recording. 
• Video record subjects for the RTRS. 
• Administer the PUTS. 
• Administer the CGI-Tics – Severity scale 
• Administer the CGI-TS – Improvement scale. 
• Administer the C-SSRS (Since Last Visit version). 
• Administer the ESRS-A. 
• Administer the Y-BOCS and SIGH-D-17. 
• AE monitoring. 
• Record concomitant medications. 
• For subjects who discontinue on or before Week 8, collect plasma sample for PK (early 
termination). 
• Instruct subjects to continue using contraception until 30 days after the last dose of study 
drug (see criteria in Section 8.1).   
9.7. 
Study Duration 
The expected duration of study participation for each subject is approximately 13 weeks, 
including up to 21 days of screening, an 8-week double-blind treatment period, and a 2-week 
drug-free follow-up period. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 34


9.8. 
Prohibitions and Restrictions 
9.8.1. 
Prior and Concomitant Medications 
The following medications are prohibited from 30 days before screening (unless otherwise 
stated) until follow-up visit (Week 10 or early termination) as described below: 
• Antiemetics:  Metoclopramide, prochlorperazine, and promethazine are prohibited. 
• Antihypertensives:  Reserpine (known to irreversibly bind to VMAT2) is prohibited. 
• Botulinum toxin:  Botulinum toxin injections are prohibited starting 90 days prior to 
screening and during the study. 
• CYP3A4 inducers:  Strong inducers of CYP3A4 (eg, phenytoin, phenobarbital, rifabutin, 
rifampin, primidone, St. John's Wort, carbamazepine) are prohibited. 
• Dopamine agonists and precursors:  Dopamine receptor agonists (eg, ropinirole) and 
precursors (eg, carbidopa/levodopa) are prohibited. 
• Dopamine antagonist: Dopamine antagonists (eg, pimozide, haloperidol, aripiprazole, 
risperidone, clozapine, olanzapine, ziprasidone) are prohibited.  
• Monoamine oxidase inhibitors (MAOIs):  All MAOIs (eg, isocarboxazid, phenelzine, 
selegiline, tranylcypromine) are prohibited. 
• VMAT-2 Inhibitors:  VMAT-2 inhibitor medications (eg, tetrabenazine, reserpine) are 
prohibited, except for study drug. 
• As needed (prn) use:  As needed use of the following medications is strictly prohibited: 
anticholinergics, benzodiazepines, antipsychotics, psychostimulants, mood stabilizers, 
antidepressants, opiates, strong CYP3A4 inhibitors, and strong CYP2D6 inhibitors. 
9.8.2. 
Dietary Restrictions 
Subjects are not permitted to consume more than 6 caffeine-containing beverages a day. 
Grapefruit juice or grapefruit products are prohibited from 7 days before Day -1 until the 
follow-up visit.  Foods containing poppy seeds are prohibited from 7 days before screening until 
the follow-up visit.  Moderate alcohol consumption (1 to 2 drinks per day or 7 to 14 drinks per 
week) is allowed from 48 hours before Day 1 until the follow-up visit. 
9.8.3. 
Other Restrictions 
Excessive use of tobacco and other products containing nicotine (including nicotine gum and 
patches) are prohibited during the study (ie, from 30 days before screening to the follow-up visit 
or early termination).  Strenuous activity beyond what is customary for the subject is prohibited 
during the study.  
Subjects must agree not to donate blood during the study, including the screening period, and 
for 4 weeks after completion of the study.  Male subjects must agree to refrain from donating 
sperm for 90 days after the last dose of study drug. 
Subjects must not have initiated CBIT during the screening period or at baseline (Day -1) or 
plan to initiate CBIT during the study. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 35


9.9. 
Withdrawal Criteria 
Subjects are free to discontinue their participation in the study at any time.  The investigator 
must withdraw any subject from the study if that subject requests to be withdrawn. 
The investigator or Sponsor must withdraw the subject from the study if the subject experiences 
any of the following: 
• If the type, frequency, or severity of any AE becomes unacceptable/intolerable. 
• If the subject is unable to tolerate the starting dose or resumption of the previous dose.   
• QTcF value >500 msec (cardiologist verified). 
• If the subject exhibits suicidal behavior, or suicidal ideation of type 4 (active suicidal 
ideation with some intent to act, without specific plan) or type 5 (active suicidal ideation 
with specific plan and intent) based on the C-SSRS. 
• Does not follow guidelines specified in the protocol. 
• Is lost to follow-up. 
• Subject is confirmed to be pregnant. 
The investigator or NBI may withdraw the subject from the study for other reasons as described 
below.  These should be discussed on a case-by-case basis with the NBI medical monitor (or 
designee) prior to withdrawing the subject from the study. 
• Develops a clinically significant laboratory (eg, ALT or AST ≥2.5 times ULN) or ECG 
abnormality. 
• Requires a medication that is prohibited by the protocol (refer to Section 9.8.1). 
• Is non-compliant with the dosing regimen (<80% dosing compliance) as verified by drug 
accountability (Refer to Section 10.6). 
All subjects prematurely discontinuing the study, regardless of cause, must have all early 
termination assessments performed (see Section 9.6.4). 
9.9.1. 
Handling of Withdrawals 
If a subject prematurely withdraws from the study at his/her request or at the investigator’s 
discretion, the investigator will record the reason for withdrawal on the relevant eCRF.  All 
subjects who withdraw from the study prematurely must have all early termination assessments 
performed. 
It is crucial to obtain follow-up data for any subject withdrawn because of an AE, abnormal 
laboratory test, vital sign measurement, physical examination, or ECG finding.  In any case, 
every effort must be made to undertake safety follow-up procedures. 
9.9.2. 
Sponsor’s Termination of Study 
Neurocrine Biosciences, Inc. (NBI) reserves the right to discontinue the study at any time for 
clinical or administrative reasons. 
Such a termination must be implemented by the investigator, if instructed to do so by NBI in a 
time frame that is compatible with the subjects’ well-being. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 36


10. 
STUDY DRUG 
10.1. 
Study Drug Supplies 
NBI or its designee will provide the study centers with subject-specific, study drug kits 
sufficient for the completion of the treatment period of the study together with the 
corresponding certificates of analysis. 
NBI-98854 will be supplied as capsules containing 40 mg of NBI-98854 (free base); and 
matching placebo capsules.  The NBI-98854 40 mg capsule is a white, opaque, HPMC No. 3 
size capsule containing 40 mg of NBI-98854 (dose is of the free base) and is formulated using 
Capsugel shells.  The placebo capsules will appear identical to the NBI-98854 capsules. 
10.2. 
Study Drug Storage 
NBI-98854 and placebo capsules must be stored at controlled room temperature (CRT) (20˚C to 
25˚C or 68˚F to 77˚F) under the conditions specified in the Investigator’s Brochure and in a 
locked area accessible only to the pharmacist (or designee) until dispensing.  Excursions outside 
this range will be allowed provided they meet the following conditions: 
• Storage between refrigerated conditions (2˚C or 36˚F) and CRT (25˚C or 77˚F) for an 
unspecified length of time. 
• Storage at temperatures above 25˚C (77˚F) but no more than 30˚C (86˚F) for up to 
3 months. 
• Storage at temperatures above 30˚C (86˚F) but no more than 40˚C (104˚F) for up to 
24 hours. 
10.3. 
Study Drug Packaging and Labeling 
All packaging and labeling operations will be performed according to Good Manufacturing 
Practice and Good Clinical Practice rules.  The study drugs will be sent to authorized staff at the 
study site.  The authorized study staff member must confirm receipt of the study drug to NBI or 
its designee via the IWRS. 
Study drug will be supplied as capsules in child-resistant blistercard dispensers; each blistercard 
contains enough study drug for 14 days of dosing plus 3 extra dose days.  The blistercards will 
contain capsules of NBI-98854 40 mg or matching placebo. 
Double-dummy study drug administration:  
Study drug will be administered in a double-dummy fashion throughout the 8-week 
double-blind treatment period.  All subjects will receive two capsules for each day of dosing as 
described below:   
• Subjects randomized to NBI-98854 40 mg will receive one 40 mg capsule and one matching 
placebo capsule.   
• Subjects randomized to receive NBI-98854 80 mg will receive 40 mg (as one 40 mg capsule 
and one matching placebo capsule) for 7 days (for dose titration) and NBI-98854 80 mg (as 
two 40 mg capsules) for the remaining 7 days plus 3 extra dose days.  Subjects will then 
receive two 40 mg capsules for each subsequent day of dosing.  
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 37


• Subjects randomized to placebo will receive two matching placebo capsules. 
Each blistercard dispenser will be labeled with a single panel label and secured with tamper 
evident seals.  Label text will include but is not limited to the protocol number, batch number, 
dosage form, route of administration, study drug kit number, sponsor name and address, 
expiration date, storage condition and the statement “Caution – New Drug: Limited by Federal 
(or US) Law to Investigational Use.” 
10.4. 
Blinding 
This study includes an 8-week double-blind placebo-controlled treatment period during which 
the subject, investigator, all study site personnel, the external video reviewer for the YGTSS 
interview, the RTRS video rater, and the Sponsor will be blinded to the subject’s treatment.  
During this treatment period, all subjects will receive NBI-98854 (doses of 40 mg or 80 mg), or 
placebo as two capsules (identical in appearance) to be self-administered once daily.   
The randomization code will be broken for an individual subject if the subject is pregnant, 
experiences an SAE that the investigator feels cannot be adequately treated without knowing the 
identity of the subject’s treatment assignment, or if required for regulatory reporting 
requirements.  All attempts to contact the NBI medical monitor (refer to Section 11.6.3 for 
contact information) must be made before unblinding a subject.  The unblinding form that 
contains the date, time, the reason the blind was broken, and name of NBI representative 
contacted must be completed. 
10.5. 
Study Drug Administration 
Study drug will be self-administered once daily in the morning (between 0700 and 1000 hours) 
at home with a standard breakfast and must swallow it with at least 4 oz. of water every day for 
the 8-week treatment period.  If a subject forgets or is unable to take the study drug during this 
time period, the subject should take his or her daily dose of study drug as soon as possible but 
no later than 1800 hours.  The subject will need to skip the dose for that day if he or she is 
unable to take the study drug before 1800 hours.  Subjects will record the date and time of study 
drug dosing each day on the form provided as part of the study drug packaging. 
10.6. 
Drug Compliance and Accountability 
Subjects will bring all unused study drug and empty study drug packaging material to the center 
at each study visit for drug accountability and reconciliation by study center personnel.  A 
compliance check will be performed by counting the capsules returned at each study visit.   
The quantity of study drug dispensed, used, and returned will be recorded on a dispensing log or 
otherwise documented.  The quantity of study drug lost or destroyed must also be accounted for 
and documented.  The designated pharmacist or qualified personnel will be responsible for 
maintaining accurate records of the quantity and dates of all study drug supplies received, 
dispensed, and returned. 
10.7. 
Study Drug Return 
Written documentation to account for study drug and study drug materials is mandatory; all 
unused study drug and study drug materials must be kept in a secure location for final 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 38


accountability and reconciliation.  Returned study drug and study drug material must be 
accounted for on a study drug return form provided by NBI or designee.  The investigator must 
provide a written explanation for any destroyed or missing study drug or study drug materials. 
Returns will be shipped to NBI or its designee at the completion of the study according to 
instructions provided by NBI or its designee.  Study drug return forms must be completed for 
the shipment of returns and sent with the study drug and study drug materials.  One copy of the 
study drug return form will be retained in the investigator’s study file. 
All returned study drug and study drug materials should be stored, inventoried, reconciled, and 
returned according to applicable state and federal regulations and study procedures. 
11. 
ADVERSE EVENTS 
All AEs, whether observed by the investigator, reported by the subject, noted from laboratory 
findings, or identified by other means, will be recorded from the time the subject signed the ICF 
until the subject’s follow-up visit (Week 10 or early termination). 
11.1. 
Definition 
An AE is any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related.  During the study, clinically significant adverse changes 
in clinical status, ECGs, laboratory values (not associated with an AE or concurrent medical 
condition), or physical examinations are considered AEs.  Any subject complaint associated 
with such an abnormal finding will also be reported as an AE. 
Adverse events include, but are not limited to:  (1) a worsening or change in nature, severity, or 
frequency of conditions present at the start of the study; (2) subject deterioration due to primary 
illness; (3) intercurrent illness; and (4) drug interaction. 
If at any time after the baseline visit (Day -1), the subject’s response to the suicidal ideation 
section of the C-SSRS is worse than the baseline assessment; it will be documented as an AE.  
All suicidal behaviors will be documented as an AE. 
Subjects should be questioned in a general way, without asking about the occurrence of any 
specific symptom.  The investigator should attempt to establish a diagnosis of the event based 
on signs, symptoms, and/or other clinical information.  In such cases, the diagnosis should be 
documented as the AE and not the individual signs/symptoms.  Following questioning and 
evaluation, all AEs, whether believed by the investigator to be related or unrelated to the study 
drug, must be documented in the subject’s medical records, in accordance with the 
investigator’s normal clinical practice and on the AE eCRF.  Each AE is to be evaluated for 
duration, intensity, frequency, seriousness, outcome, other actions taken, and relationship to the 
study drug.  
The following are not considered AEs: 
• Continuous persistent disease/symptom present before drug administration, unless it 
unexpectedly progresses, or increases in severity following drug administration 
• Recurrence of TS symptoms, unless worsened from baseline 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 39


• Pregnancy 
11.2. 
Intensity of Adverse Events 
Adverse events must be graded for intensity.  An intensity category of mild, moderate, or 
severe, as defined in Table 3, must be entered on the AE eCRF.  It should be noted that the term 
“severe” used to grade intensity is not synonymous with the term “serious.” 
Table 3: 
Intensity of Adverse Events 
Grade  
Intensity 
Mild 
An AE that is usually transient and may require only minimal treatment or 
therapeutic intervention.  The event does not generally interfere with usual activities 
of daily living. 
Moderate 
An AE that is usually alleviated with additional specific therapeutic intervention.  
The event interferes with usual activities of daily living, causing discomfort but 
poses no significant or permanent risk of harm to the research participant. 
Severe 
An AE that interrupts usual activities of daily living, or significantly affects clinical 
status, or may require intensive therapeutic intervention. 
 
11.3. 
Relationship to Study Drug 
The investigator will document his/her opinion of the relationship of the AE to treatment with 
study drug using the criteria outlined in Table 4.  An AE is deemed associated with the use of 
the study drug “if there is a reasonable possibility that the drug caused the AE” (otherwise 
referred to as a suspected adverse reaction).  Reasonable possibility means there is evidence to 
suggest a causal relationship between the drug and the adverse event (Title 21 CFR 312.32 [a]). 
Table 4: 
Relationship of Adverse Events to Study Drug 
Relationship 
Description 
Definite 
A reaction that follows a reasonable temporal sequence from administration of the drug or in 
which the drug level has been established in body fluids or tissue; that follows a known or 
expected response pattern to the suspected drug; and that is confirmed by improvement on 
stopping or reducing the dosage of the drug, and reappearance of the reaction on repeated 
exposure. 
Possible 
An adverse event in which there is reasonable possibility that the drug caused the event.  
Reasonable possibility means there is evidence to suggest a causal relationship between the 
drug and the adverse event. 
Unlikely 
A reaction that follows a reasonable temporal sequence from administration of the drug; that 
follows a known or suspected response pattern to the suspected drug; but that could 
reasonably be explained by known characteristics of the subject’s clinical state. 
Not Related 
Any event that does not meet the above criteria. 
11.4. 
Recording Adverse Events 
For randomized subjects, each AE will be listed as a separate entry on an AE eCRF.  Screen 
failure subjects will have AE information noted in the source documentation.  The investigator 
(or designee) will provide information on dates and times of onset and resolution, intensity, 
seriousness, frequency, action(s) taken, changes in study drug usage, relationship to study drug, 
and outcome. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 40


The following categories of medical events that could occur during participation in a clinical 
study must be reported within 24 hours to NBI or its designee: 
• Serious adverse event, including death (Refer to Section 11.6). 
• Pregnancy (refer to Section 11.7). 
• Events of suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with 
some intent to act, without specific plan) or type 5 (active suicidal ideation with specific 
plan and intent) based on the C-SSRS. 
11.5. 
Post-Study Follow-Up of Adverse Events 
All AEs, including clinically significant changes in ECGs, physical examination findings, or 
isolated clinically significant laboratory findings must be followed until the event resolves, the 
condition stabilizes, the event is otherwise explained, or the subject is lost to follow-up.  If 
resolved, a resolution date should be documented on the eCRF.   
Adverse events ongoing at the follow-up visit or early termination will be followed for as long 
as necessary to adequately evaluate the subject’s safety or until the event stabilizes or resolves 
or until the subject is lost to follow up.  The investigator is responsible for ensuring that follow 
up includes any supplemental investigations as may be indicated to elucidate the nature and/or 
causality of the AE.  This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals, as is 
practical. 
11.6. 
Serious Adverse Events 
All SAEs will be recorded from the time the subject has signed the ICF until 30 days after the 
last dose of study drug. 
11.6.1. 
Definition of a Serious Adverse Event 
An SAE is any AE that results in any of the following outcomes: 
• Death. 
• A life threatening adverse event.  Life threatening means that the subject was, in the view of 
the investigator or sponsor, at immediate risk of death from the reaction as it occurred.  It 
does not mean that hypothetically the event might have caused death if it occurred in a more 
serious form. 
• Inpatient hospitalization or prolongation of existing hospitalization.  Hospitalization for 
elective treatment or a preexisting condition that did not worsen during the clinical 
investigation is not considered an AE.  Hospitalization or nursing home admission for the 
purpose of caregiver respite is not considered an AE.  Complications that occur during 
hospitalization are AEs, and if a complication prolongs hospitalization, the event is 
considered serious.  Treatment in a hospital emergency room is not a hospitalization. 
• A persistent or significant incapacity or substantial disruption of a person’s ability to 
conduct normal life functions. 
• A congenital anomaly/birth defect. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 41


• Important medical events that may not result in death, be life threatening, or require 
hospitalization.  These events may be considered serious when, based on appropriate 
medical judgment, they may jeopardize the health of the subject and may require medical or 
surgical intervention to prevent one of the outcomes listed.  Any other event thought by the 
investigator to be serious should also be reported, following the reporting requirements 
detailed in this section.  Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias, 
convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse. 
11.6.2. 
Managing Serious Adverse Events 
Subjects experiencing an SAE or an emergency situation will be examined by a physician as 
soon as possible.  The physician in attendance will do whatever is medically needed for the 
safety and well-being of the subject.  The subject will remain under observation as long as 
medically indicated.  Appropriate laboratory studies will be conducted until all parameters 
return to normal or are otherwise explained or stable.  The subject will be followed until the 
SAE resolves or until the subject is medically stabilized.  The investigator (or designee) will 
notify the medical monitor (and the IRB, if necessary) immediately (within 24 hours) of the 
SAE and the outcome of the SAE. 
If within the time of informed consent until 30 days after the last dose of study drug, an 
investigator becomes aware of an SAE, then the event must be documented and reported as 
described in Section 11.6.3. 
11.6.3. 
Reporting Serious Adverse Events and Other Immediately Reportable Events 
Serious AEs and other immediately reportable events (defined in Section 11.4) must be reported 
within 24 hours of first knowledge of the event by study personnel to the NBI medical monitor 
or NBI Clinical Drug Safety (CDS) Department.  Reports of SAEs or pregnancies should be 
followed by a fax or email of the SAE or Pregnancy Form.  It is important that the investigator 
provide his or her assessment of relationship to study drug at the time of the initial SAE report.  
For SAEs or Other Immediately Reportable Events, contact CDS: 
 
CDS telephone: (866) 626-7792 or (858) 617-7792 
 
CDS facsimile: 
(888) 617-7551 
 
CDS e-mail:  
cds@neurocrine.com 
 
NBI Medical Monitor:  
Telephone: 
(858) 617-7250 
 
 
 
 
 
 
 
 
 
Cell phone: 
(858) 431-6012 
11.6.4. 
Expedited Safety Reports 
Neurocrine Biosciences, Inc. or its representatives will submit an Expedited Safety Report for 
any suspected adverse reaction (as defined in Section 11.3) that is considered both serious and 
unexpected within 15 calendar days and for any unexpected fatal or life threatening experience 
within 7 calendar days via telephone or facsimile; or according to country specific regulations. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 42


Neurocrine Biosciences, Inc. or its representatives will send copies of each Safety Report 
submitted to regulatory authorities to the investigators.  The safety report must be submitted to 
the appropriate IRB as soon as possible.  Documentation of the submission to the IRB and 
receipt by the IRB (if applicable) must be retained for each safety report. 
11.7. 
Pregnancy 
Pregnancy is neither an AE nor an SAE unless the criteria for an SAE are met.  However, all 
pregnancies in female subjects who received NBI-98854 will be followed to assess for 
congenital anomaly.  Subjects must be counseled at all visits to continue using two forms of 
nonhormonal contraception or hormonal contraception (see inclusion criterion #10 in 
Section 8.1) until 30 days after the last dose of study drug.  If at any time between the time the 
subject signs the ICF and the last study visit a subject believes she is pregnant, the subject will 
be instructed to stop taking the study medication and return to the study center within 24 hours 
and undergo a serum pregnancy test to confirm pregnancy. 
All confirmed pregnancies, in subjects who received study drug, must be immediately reported 
to NBI (refer to Section 11.6.3 for contact information), followed by fax or email of the 
pregnancy form to NBI CDS.  A first trimester ultrasound will be required for all confirmed 
pregnancies.  Pregnancies in subjects who received NBI-98854 will be followed until resolution 
(ie, termination [voluntary or spontaneous] or birth). 
12. 
DOCUMENTATION OF DATA 
12.1. 
Case Report Form 
The CRF data for this study are being collected with an electronic data capture (EDC) system 
(Rave®) provided by Medidata Solutions Incorporated, NY, USA.  The EDC system and the 
study-specific eCRFs will comply with Title 21 CFR Part 11.  The documentation related to the 
validation of the EDC system is available through the vendor, Medidata, while the validation of 
the study specific eCRFs will be conducted by NBI and the required documentation will be 
maintained in the Trial Master File. 
The investigator will document subject data in his/her own subject files.  These subject files will 
serve as source data for the study.  All eCRF data required by this protocol will be recorded by 
authorized study personnel in the EDC system, with the exception of data captured in an 
electronic format, which will be loaded electronically into the appropriate eCRFs.  All data 
entered into the eCRF will be supported by source documentation.  The eCRF for each subject 
must be reviewed by the investigator and signed on the appropriate eCRF page(s).  This should 
be done as soon as possible after the subject completes the study.   
The investigator or an authorized member of the investigator's staff will make any necessary 
additions/corrections to the eCRF.  All change information, including the date, person 
performing the corrections, and reason for the change will be available via the electronic audit 
trail, which is part of the EDC system.  The eCRFs will be reviewed periodically for 
completeness, legibility, and acceptability by NBI (or designee).  NBI will also be allowed 
access to all source documents and medical records pertinent to the study in order to verify 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 43


eCRF entries.  The Principal Investigator will review the eCRFs for completeness and accuracy 
and enter his or her electronic signature on the eCRFs as evidence thereof. 
Medidata will provide access to the Neurocrine portal of the EDC system for the duration of the 
study through a password-protected method of internet access.  Such access will be removed 
from investigator sites at the end of the site's participation in the study.  Data from the EDC 
system will be archived on appropriate data media (CD ROM, etc.) and provided to the 
investigator at that time as a durable record of the site’s eCRF data.  Although not required, the 
investigator may make paper printouts from that media. 
All clinical work conducted under this protocol is subject to GCP regulations.  This includes an 
inspection by NBI and/or health authority representatives at any time.  The Principal 
Investigator will agree to the inspection of study-related records by health authority 
representatives and/or NBI. 
12.2. 
Data Capture, Review, and Validation 
Data entered in the EDC system will be verified against the source data by NBI (or designee).  
Any discrepancies will be corrected on-line by authorized site personnel.  After completion of 
the entry process, automated (computer-generated) logic checks will run in order to identify 
items such as inconsistent study dates.  In addition, manual review/checks may be performed by 
NBI on the data.  Any inconsistencies/errors/omissions identified will be sent to the site (via an 
electronic query) for the necessary corrections to be made to the eCRF.  Once entered and saved 
in an eCRF, data immediately become part of the study database and are available to NBI. 
12.3. 
Coding Dictionaries 
Adverse events and medical history will be coded using the chosen version of the Medical 
Dictionary for Regulatory Activities (MedDRA).  Prior and concomitant medications will be 
coded using the chosen version of the World Health Organization Drug Dictionary (WHO 
Drug). 
13. 
STATISTICAL AND ANALYTICAL PLAN 
Descriptive and inferential statistical methods will be used to evaluate and summarize the data 
from this study.  The term “descriptive statistics” refers to the number of subjects (n), mean, 
median, standard deviation (SD), standard error of the mean (SEM), minimum, and maximum 
for continuous and ordinal categorical variables; and refers to the number and percentage of 
subjects for categorical variables.  The term “inferential statistics” refers to hypothesis tests 
which will be performed to assess differences between each NBI-98854 treatment group and 
placebo for selected efficacy variables. 
The primary efficacy endpoint in this study is the YGTSS TTS mean change from baseline 
(Day -1) to Week 8.  Inferential statistics will be calculated for this endpoint as well as for other 
(secondary) efficacy endpoints, which include the YGTSS Global Tic Severity score mean 
change from baseline to Week 8, the RTRS total score mean change from baseline to Week 8, 
the PUTS total score mean change from baseline to Week 8, and the CGI-TS-Improvement 
mean score change from baseline to Week 8, and the CGI-Tics-Severity mean score change 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 44


from baseline to Week 8.  Exploratory analyses of the Week 2, Week 4, and Week 6 values of 
these endpoints will be performed also.  Nominal two-sided p-values will be reported for all 
hypothesis tests (ie, without any adjustments for multiplicity). 
The analysis plan provided in this protocol represents a brief description of the planned 
analyses.  A comprehensive and detailed statistical analysis plan (SAP) will be generated prior 
to final study database lock and treatment unblinding.  The SAP may include a number of 
additional analyses and data summaries not described in this protocol. 
13.1. 
Analysis Sets 
Three analysis sets will be defined for this study.  The safety analysis set will include all 
subjects who are randomized to a treatment group and receive at least one dose of study drug.  
The intent-to-treat (ITT) analysis set will include all subjects in the safety analysis set who have 
at least one evaluable TTS during the 8-week double-blind treatment period.  The per-protocol 
(PP) analysis set will include all subjects in the ITT analysis set who have no efficacy-related 
important protocol deviations.  Additional PP analysis set criteria may be specified in the SAP. 
13.2. 
Sample Size 
The study sample size of 30 subjects per treatment group is based on a power calculation for the 
TTS change from baseline using a two-sample t-test with a two-sided Type I error of 0.05.  This 
sample size provides 80% power to detect an effect size of approximately 0.75 and 90% power 
to detect an effect size of approximately 0.85.  Note that the effect size is defined as an 
NBI-98854 treatment group vs. placebo mean difference divided by the common SD.   
Effect sizes for the TTS from published reports of placebo-controlled TS trials generally range 
from approximately 0.6 to slightly greater than 1.0 (Jankovic et al, 2010, Yoo et al, 2013, 
ClinicalTrials NCT01727700).  The effect sizes of 0.75 and 0.85 mentioned in the above 
paragraph are representative of effect sizes seen in clinical studies with other drugs being 
evaluated for the treatment of TS. 
13.3. 
Handling of Missing Data 
Conventions for the handling of missing data will be described in the SAP. 
13.4. 
Enrollment and Disposition of Subjects 
The summary of subject enrollment and disposition will display the number of subjects who 
were randomized to each treatment group, who received at least one dose of study drug, who 
completed the 8-week treatment period, and who completed the study.  The number of subjects 
who did not complete the study will be summarized also, both overall and according to the 
reason for early discontinuation. 
13.5. 
Demographics and Baseline Characteristics 
Demographic data (age, gender, race, and ethnicity) and baseline characteristics (including 
height, weight, BMI, CYP2D6 genotype status, age at TS diagnosis, and baseline values for the 
TTS score) will be summarized with descriptive statistics for each treatment group and for the 
overall study population.  Medical history will also be summarized. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 45


13.6. 
Study Drug Dosing and Compliance 
The number of doses of study drug taken during the double-blind, placebo-controlled treatment 
period will be summarized with descriptive statistics by visit (Weeks 2, 4, 6, and 8).  The 
cumulative estimated number of doses taken through Week 8 will be summarized as well.  
Additionally, the number of dose reductions will be summarized. 
13.7. 
Pharmacokinetic Data 
The plasma concentrations of NBI-98854 and the metabolite NBI-98782 will be summarized 
with descriptive statistics by visit (Weeks 2, 4, 6, 8, and 10).  Concentrations below the lower 
limit of quantification will be set equal to zero for all plasma concentration summaries. 
13.8. 
Efficacy Data 
The efficacy measures in this study include the YGTSS, RTRS, PUTS, CGI-Tics-Severity, and 
CGI-TS–Improvement.  A number of derived variables based on these measures (eg, the TTS) 
will be summarized with descriptive statistics by visit, and inferential statistics will be 
calculated for selected variables as described in the following paragraphs.  The SAP will 
provide a full description of the derived variables that will be summarized for these efficacy 
measures. 
The TTS changes from baseline (Day -1) and the Global Tic Severity score changes from 
baseline (Day -1) at Weeks 2, 4, 6, and 8 will be analyzed with a mixed-effects model repeated 
measures (MMRM) model which includes the baseline value as a covariate and treatment group 
(placebo, NBI-98854 40 mg, or NBI-98854 80 mg), visit (Week 2, 4, 6, or 8), treatment group 
by visit interaction, and baseline by visit interaction as fixed effects.  Subject will be included as 
a random effect. 
Least-squares (LS) mean differences between each NBI-98854 treatment group and placebo at 
each visit will be tested for significance and summarized with 2-sided 95% confidence intervals.  
Nominal 2-sided p-values will be reported for all hypothesis tests.  Note that the primary 
comparisons of interest are those for the Week 8 visit; comparisons at Weeks 2, 4, and 6 are 
considered to be exploratory.   
Similar MMRM analyses will be performed for the RTRS total score and PUTS total score.   
The CGI-Tics – Severity and CGI-TS-Improvement will be summarized by visit with both 
continuous variable descriptive statistics (using numeric scores which range from 1 through 7) 
and with frequency tables (based on the response category descriptors).  Additionally, the 
percentage of subjects who are “Much Improved” or “Very Much Improved” on the 
improvement scale will be summarized.   
Hypothesis tests comparing each NBI-98854 treatment group to placebo at Weeks 2, 4, 6, and 8 
will be performed for the numeric CGI-Tics – Severity and CGI-TS-Improvement scores using 
an MMRM model similar to the model described above for the TTS, but without a baseline 
covariate. 
The descriptive and inferential statistical summaries for the efficacy variables will be presented 
for both the ITT and PP analysis sets. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 46


13.9. 
Safety Data 
Treatment-emergent AEs, categorized by system organ class (SOC) and preferred term (PT) as 
defined by the MedDRA, will be summarized in frequency tables.  The TEAE summary tables 
will include the number of events, number of unique subjects experiencing each event, and 
percentage of subjects experiencing each event. 
Summary tables will be presented including all TEAEs, only TEAEs that are considered to be 
possibly or definitely related to study drug, and TEAEs according to maximum intensity. 
Additional summaries will be presented for TEAEs leading to premature discontinuation from 
the study, SAEs, and deaths. 
Clinical laboratory, serum prolactin, vital signs, ECG, C-SSRS, ESRS-A, Y-BOCS, and SIGH-
D-17 data will be summarized by visit with descriptive statistics.  Clinically significant physical 
examination findings will be displayed in a data listing.  Prior and concomitant medications will 
also be summarized. 
13.10. 
Software 
Statistical calculations and summaries will be generated using SAS software version 9.3 or 
later. 
13.11. 
Interim Analysis 
An interim analysis is not planned for this study. 
14. 
REGULATORY AND ETHICAL ISSUES 
14.1. 
General Legal References 
The study will be carried out according to the provision of the US CFR, the US FDA, and the 
International Conference on Harmonisation Guidelines (ICH) for GCP.  All clinical work 
conducted under this protocol is subject to GCP rules.  This includes an inspection by NBI or its 
representative, health authority or IRB representatives at any time.  The investigator must agree 
to the inspection of study related records by health authority representatives and/or NBI or its 
designee. 
14.2. 
Institutional Review Board 
The final approved protocol and the ICF will be reviewed by the IRB for the clinical site.  The 
committee’s decision concerning conduct of the study will be sent in writing to the investigator 
and a copy will be forwarded to NBI.  The investigator must agree to make any required 
progress reports to the IRB, as well as reports of SAEs, life threatening problems, or death.  
14.3. 
Protocol Adherence and Amendments 
The protocol must be read thoroughly and the instructions must be followed exactly.  Any 
changes in the protocol will require a formal amendment.  Such amendments will be agreed 
upon and approved in writing by the investigator and NBI.  The IRB will be notified of all 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 47


amendments to the protocol.  Amendments to the protocol will not be implemented until written 
IRB approval has been received.  
14.4. 
Required Documents 
The investigator must provide to NBI or its representatives the following documents before the 
enrollment of any subject (copies should be kept by the investigator in the investigator’s 
regulatory document binder): 
• Signed copy (original) of the approved protocol. 
• Completed and signed statement of investigator (Form FDA 1572). 
• Curriculum vitae and current medical license of the investigator and subinvestigators. 
• Financial disclosure information as required. 
• Letter of approval from the IRB for both protocol and consent form. 
• Copy of the IRB approved written ICF to be used. 
• Laboratory documents (certifications/accreditations, normal ranges) if not provided by a 
central laboratory. 
14.5. 
Informed Consent 
All subjects will provide their written informed consent before the performance of any study 
related procedures. 
Each subject’s chart will include the signed ICF for study participation.  When the study 
treatment is completed and the eCRF has been monitored, the ICF will be kept in the 
investigator’s central study file.  Regulatory authorities may check the existence of the signed 
ICF in this central study folder if not having done so during the study. 
14.6. 
Study Monitoring 
Throughout the course of the study, the study monitor will make frequent contacts with the 
Investigator.  This will include emails, telephone calls, and on-site visits.  During the on-site 
visits, the eCRFs will be reviewed for completeness and adherence to the protocol.  As part of 
the data audit, source documents will be made available for review by the study monitor.  The 
study monitor will also perform drug accountability checks and may periodically request review 
of the investigator study file to ensure completeness of documentation in all respects of clinical 
study conduct. 
Upon completion of the study, the study monitor will arrange for a final review of the study 
files after which the files should be secured for the appropriate time period.  The investigator or 
appointed delegate will receive the study monitor during these on-site visits, will cooperate in 
providing the documents for inspection, and respond to inquiries.  In addition, the investigator 
will permit inspection of the study files by authorized representatives of the regulatory agencies. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 48


14.7. 
Quality Assurance 
The study will be conducted in accordance with NBI’s standard operating procedures designed 
to ensure that all procedures are in compliance with GCP and FDA Guidelines, Health Canada 
Guidelines, and according to national law.  Quality assurance audits may be performed at the 
discretion of NBI. 
14.8. 
Record Retention 
Federal regulations require that records of drug disposition, CRFs, and all reports of this 
investigation shall be retained by the investigator for a minimum of 2 years after notification by 
NBI that the regulatory authorities have been notified of the study's termination, or 2 years after 
approval of the marketing application.  If the investigator is unable to retain the study 
documents for the required amount of time, NBI must be informed of the individual who will be 
assuming this responsibility. 
14.9. 
Confidentiality 
NBI and the clinical site affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy.  Throughout this study, all data will be identified only by an 
identification number and, where applicable, subject’s initials and birth date. 
All information concerning this study and which was not previously published is considered 
confidential information.  This confidential information shall remain the sole property of NBI; it 
shall not be disclosed to others without written consent of NBI; and shall not be used except in 
the performance of this study. 
The information compiled during the conduct of this clinical study is also considered 
confidential and may be disclosed and/or used only by NBI as deemed necessary.  To allow the 
use of the information derived from this clinical study and to ensure compliance with current 
federal regulations, the investigator is obliged to furnish NBI with the complete test results and 
all data compiled in this study. 
15. 
STUDY COMMENCEMENT AND DISCONTINUATION 
Upon satisfactory receipt of all required regulatory documents, NBI (or designee) will arrange 
that all study material be delivered to the study site.  Subject entry should not begin until after 
the required regulatory documents are confirmed as received and the Investigator 
Meeting/Initiation Meeting has occurred.  All personnel expected to be involved in the conduct 
of the study will undergo orientation to include review of study protocol, instructions for eCRF 
completion, AE reporting, and overall responsibilities including those for drug accountability 
and study file maintenance. 
If the study is discontinued, all subjects should undergo a complete follow up examination.  
Any clinically relevant finding, including laboratory values of potential clinical concern, and 
adverse experiences will be followed until they resolve or return to a clinically acceptable level. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505 
Clinical Study Protocol Amendment No. 3 Final Version
 
Confidential
29 June 2016
Page 49


16.
REFERENCES
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition. 1994. 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition. 2013. 
Baxter LR and Guze BH (1993). Neuroimaging.  In: Kurlan, R. (Ed), Handbook of Tourette 
syndrome and related tic and behavioral disorders.  Rochester: Marcel Decker Inc. 
Braun AR, Stoetter B, Randolph C, Hsiao JK, Vladar K, Gernert J, et al. The functional 
neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral 
glucose metabolism differentiating patients and controls. Neuropsychopharmacology. 1993 
Dec;9(4):277-91. 
Cavanna AE and Nani A. Tourette syndrome and consciousness of action. Tremor Other 
Hyperkinet Mov (NY). 2013 Sep 23;3. 
Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic 
movement disorders: a review of the literature. Clin Therapeutics. 2012; 34:1487-1504. 
Chouinard S and Ford B. Adult onset tic disorders. J Neurol Neurosurg Psychiatry. 2000 
Jun;68(6):738-43. 
Chouinard G and Margolese HC.  Manual for the Extrapyramidal Symptom Rating Scale 
(ESRS).  Schizophr Res. 2005 Jul 15;76(2-3):247-65. 
ClinicalTrials.gov Identifier: NCT01727700. Otsuka Pharmaceutical Development & 
Commercialization, Inc. Study evaluating the safety and efficacy of fixed-dose once-daily 
aripiprazole in children and adolescents with Tourette’s Disorder 
https://www.clinicaltrials.gov/ct2/show/NCT01727700?term=NCT01727700&rank=1 
[Accessed 05 June 2015]. 
Felling RJ and Singer HS. Neurobiology of Tourette syndrome: current status and need for 
further investigation. J Neurosci. 2011 Aug 31;31(35):12387-95. 
Goetz CG, Pappert EJ, Louis ED, Raman R, Leurgans S. Advantages of a modified scoring 
method for the Rush Video-based Tic Rating Scale. Mov Disord. 1999 May;14(3):502-6. 
Jankovic J and Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. 
Neurology 1997; 48(2):358-362. 
Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled 
study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 
Jan;81(1):70-3. 
Jankovic J and Kurlan R. Tourette syndrome: evolving concepts. Mov Disord. 2011 
May;26(6):1149-56. 
Kurlan R. Clinical practice. Tourette's Syndrome. N Engl J Med. 2010 Dec 9;363(24):2332-8. 
Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The Yale 
Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad 
Child Adolesc Psychiatry. 1989 Jul;28(4):566-73. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505
Clinical Study Protocol Amendment No. 3 Final Version
Confidential
29 June 2016
Page 50


Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, et al. Course of tic severity in 
Tourette syndrome: the first two decades. Pediatrics. 1998 Jul;102(1 Pt 1):14-9. 
Ondo WG, Hanna PA, Jankovic J.  Tetrabenazine treatment for tardive dyskinesia: assessment 
by randomized videotape protocol. Am J Psychiatry 1999; 156(8):1279 1281. 
Pourfar M, Feigin A, Tang CC, Carbon-Correll M, Bussa M, Budman C, et al.  Abnormal 
metabolic brain networks in Tourette syndrome. Neurology. 2011 Mar 15;76(11):944-52. 
Robertson MM. Gilles de la Tourette syndrome: the complexities of phenotype and treatment. 
Br J Hosp Med (Lond). 2011 Feb;72(2):100–7. 
Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, Münchau A. Pharmacological 
treatment of tic disorders and Tourette Syndrome. Neuropharmacology. 2013 May;68:143-9. 
Shprecher D and Kurlan R. The management of tics. Mov Disord. 2009 Jan 15;24(1):15-24. 
Swain JE, Scahill L, Lombroso PJ, King RA, Leckman JF. Tourette syndrome and tic disorders: 
a decade of progress. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):947–68. 
Woods DW, Piacentini J, Himle MB, Chang S. Premonitory Urge for Tics Scale (PUTS): initial 
psychometric results and examination of the premonitory urge phenomenon in youths with Tic 
disorders. J Dev Behav Pediatr. 2005 Dec;26(6):397-403. 
Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, et al. A multicenter, randomized, 
double-blind, placebo-controlled study of aripiprazole in children and adolescents with 
Tourette’s disorder. J Clin Psychiatry. 2013;74(8):e772-80. 
Neurocrine Biosciences, Inc., Study No. NBI-98854-1505
Clinical Study Protocol Amendment No. 3 Final Version
Confidential
29 June 2016
Page 51

SAP_001.pdf: 
Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
1 
STATISTICAL ANALYSIS PLAN 
PHASE 2 
FINAL 
DATE OF PLAN: 
14Dec2016 
STUDY DRUG: 
NBI-98854 
PROTOCOL NUMBER: 
NBI-98854-1505 
STUDY TITLE: 
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy 
of NBI-98854 in Adult Subjects with Tourette Syndrome 
SPONSOR: 
Neurocrine Biosciences, Inc. 
12780 El Camino Real 
San Diego, CA  92130 
Telephone:  (858) 617-7600 
CONFIDENTIAL 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
SIGNATURE PAGE 
This document has been prepared by: 
<<Printed Name>>, Project Statistician 
Neurocrine Biosciences, Inc. 
This document has been reviewed and accepted by: 
<<Printed Name>>, <<Title>> 
Neurocrine Biosciences, Inc. 
Signature 
Signature 
2 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
3 
 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS ..........................................................................................................6 
1. 
INTRODUCTION ........................................................................................................8 
2. 
STUDY OBJECTIVES ................................................................................................8 
2.1. 
Study Design and Assessments ....................................................................................8 
3. 
STATISTICAL ANALYSES .....................................................................................10 
3.1. 
General Statistical Procedures ....................................................................................10 
3.2. 
Sample Size Calculation .............................................................................................10 
3.3. 
Pooling of Sites ...........................................................................................................11 
3.4. 
Handling of Early Termination Visit Data .................................................................11 
3.5. 
Handling of Missing Data ...........................................................................................11 
3.5.1. 
Missing and incomplete dates .....................................................................................12 
3.6. 
Coding Dictionary ......................................................................................................12 
3.7. 
Analysis Sets ...............................................................................................................13 
3.7.1. 
Definition of Analysis Sets .........................................................................................13 
3.7.2. 
Summary of Analysis Sets ..........................................................................................13 
3.7.3. 
Application of Analysis Sets ......................................................................................13 
3.8. 
Subject Randomization and Disposition .....................................................................14 
3.9. 
Important Protocol Deviations ....................................................................................14 
3.10. 
Demographic Data and Baseline Characteristics ........................................................15 
3.11. 
Medical History ..........................................................................................................15 
3.12. 
Study Drug Dosing Compliance .................................................................................15 
3.13. 
Dose Reduction Summary ..........................................................................................16 
3.14. 
Pharmacokinetic Data .................................................................................................16 
3.15. 
Efficacy Data ..............................................................................................................17 
3.15.1. 
Efficacy Endpoints ......................................................................................................17 
3.15.2. 
Primary Efficacy Endpoint .........................................................................................18 
3.15.3. 
Key Secondary Efficacy Endpoint ..............................................................................20 
3.15.4. 
Fixed-Sequence Testing Procedure to Control for Multiple Comparisons ................20 
3.15.5. 
Sensitivity Analyses for Primary Efficacy Endpoint ..................................................21 
3.15.6. 
Secondary Efficacy Endpoints ....................................................................................23 
3.15.6.1. 
YGTSS TTS Responder Analysis ..............................................................................23 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
4 
 
3.15.6.2. 
YGTSS Impairment Score ..........................................................................................24 
3.15.6.3. 
YGTSS Global Tic Severity Score .............................................................................24 
3.15.6.4. 
Rush Video-based Tic Rating Scale (RTRS) ..............................................................25 
3.15.6.5. 
Premonitory Urge for Tics Scale (PUTS) ...................................................................25 
3.15.6.6. 
CGI-Tics-Severity .......................................................................................................26 
3.15.6.7. 
CGI-TS-Improvement Responder Analysis ...............................................................27 
3.16. 
Safety Data ..................................................................................................................27 
3.16.1. 
Adverse Events ...........................................................................................................27 
3.16.1.1. 
Adverse Event Overall Summary ...............................................................................28 
3.16.1.2. 
Adverse Events Resulting in Study Drug Dose Reductions .......................................28 
3.16.1.3. 
Adverse Events Resulting in Premature Study Discontinuation ................................28 
3.16.1.4. 
Deaths and Other Serious Adverse Events .................................................................28 
3.16.2. 
Clinical Laboratory Data ............................................................................................29 
3.16.3. 
Physical Examination and Weight ..............................................................................31 
3.16.4. 
Vital Signs ..................................................................................................................31 
3.16.5. 
Electrocardiogram .......................................................................................................31 
3.16.6. 
Columbia-Suicide Severity Rating Scale (C-SSRS) ...................................................32 
3.16.7. 
Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) ...............................33 
3.16.8. 
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) ...............................................34 
3.16.9. 
Structured Interview Guide for the Hamilton Depression Rating Scale 
(SIGH-D-17) ...............................................................................................................34 
3.16.10. 
Prior and Concomitant Medications ...........................................................................35 
3.17. 
Additional Data Presentations ....................................................................................35 
3.17.1. 
Inclusion and Exclusion Criteria ................................................................................35 
3.17.2. 
Serology Test Results .................................................................................................35 
3.17.3. 
Pregnancy Test Results ...............................................................................................35 
3.17.4. 
Urine Drug Screen and Alcohol Breath Test ..............................................................36 
4. 
DEVIATIONS FROM PROTOCOL PLANNED ANALYSIS .................................36 
5. 
PERFORMANCE QUALIFICATION OF SAS® PROGRAMS ...............................36 
6. 
REFERENCES ...........................................................................................................37 
 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
5 
 
LIST OF TABLES 
Table 1: 
Allowable Study Day Range for Early Termination Visit Mapping ..........................11 
Table 2: 
Data Summaries by Analysis Set ................................................................................14 
Table 3: 
Efficacy Endpoints and Classification ........................................................................18 
Table 4: 
Potential Clinically Significant Criteria for Clinical Laboratory Variables ...............30 
Table 5: 
Potentially Clinically Significant Criteria for Vital Signs ..........................................31 
 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
6 
LIST OF ABBREVIATIONS 
Abbreviation 
Term 
AE
Adverse event
ALT
Alanine aminotransferase
ANCOVA 
Analysis of covariance 
ANOVA 
Analysis of variance 
AST
Aspartate aminotransferase
ATC 
Anatomical Therapeutic Chemical Classification 
BLQ 
Below the limit of quantification 
BOCF 
Baseline observation carried forward 
CGI-Tics 
Clinical Global Impression of Tics 
CGI-TS 
Clinical Global Impression of Change – Tourette Syndrome 
C-SSRS
Columbia-Suicide Severity Rating Scale 
CYP2D6
Cytochrome P450 2D6
ECG
Electrocardiogram
eCRF
Electronic case report form 
ESRS-A
Extrapyramidal Symptom Rating Scale - Abbreviated 
ET
Early termination
GGT
Gamma-glutamyl transferase
HBsAg
Hepatitis B surface antigen 
HCV-Ab
Hepatitis C antibody 
HIV-Ab
Human immunodeficiency virus antibody 
IPD
Important protocol deviation 
ITT
Intent-to-treat
J2R
Jump to reference 
LS
Least squares
MAR
Missing at random 
MedDRA
Medical Dictionary for Regulatory Activities 
MMRM
Mixed-effect model repeated measures 
n, N
Sample size (number of subjects) 
NBI
Neurocrine Biosciences, Inc. 
PCS
Potentially Clinically Significant 
PK
Pharmacokinetic(s)
PP
Per-protocol


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
7 
 
Abbreviation 
Term 
PT 
Preferred term 
PUTS 
Premonitory Urge for Tics Scale 
QTcF 
Fridericia’s correction of QT interval  
RTRS 
Rush Video-Based Tic Rating Scale 
SAE 
Serious adverse event 
SAP 
Statistical Analysis Plan 
SAS® 
SAS®  statistical software 
SD 
Standard deviation 
SEM 
Standard error of the mean 
SIGH-D-17 
Structured Interview Guide for the Hamilton Depression Rating Scale, 17-Item 
SOC 
System organ class 
TEAE 
Treatment-emergent adverse event 
TS 
Tourette Syndrome 
TTS 
Total Tic Score 
WHO 
World Health Organization 
Y-BOCS 
Yale-Brown Obsessive-Compulsive Scale 
YGTSS 
Yale Global Tic Severity Scale 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
8 
 
1. 
INTRODUCTION 
This statistical analysis plan (SAP) provides a detailed description of the analyses, tables, 
figures, and listings that will be prepared to summarize the data from the Phase 2 study described 
in Neurocrine Biosciences, Inc. (NBI) Protocol NBI-98854-1505. 
2. 
STUDY OBJECTIVES 
The objectives of this clinical study are as follows: 
 To evaluate the efficacy of 2 active doses of NBI-98854 (40 mg and 80 mg) administered 
once daily in adult subjects with Tourette syndrome (TS). 
 To assess the safety and tolerability of repeated daily doses of NBI-98854 in adult subjects 
with TS. 
 To evaluate plasma exposure of NBI-98854 and its metabolite, NBI-98782, following 
repeated daily doses of NBI-98854. 
2.1. 
Study Design and Assessments 
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group 
study in a total of approximately 90 male and female subjects, 18 to 64 years of age, with a 
Diagnostic and Statistical Manual of Mental Disorders, 4th or 5th Editions, diagnosis of TS.   
After providing informed consent, subjects will be screened to determine eligibility within 
21 days (Days -21 to -1) before the start of study drug dosing on Day 1.  Subjects may also be 
asked to sign an optional release form to allow their Rush Video-based Tic Rating Scale (RTRS) 
video recordings to be used for educational purposes.   
On Day -1 (baseline), eligible subjects will return to the study center for collection of baseline 
safety and efficacy assessments and collection of a blood sample for subsequent determination of 
their cytochrome P450 2D6 (CYP2D6) metabolizer status.  Subjects who continue to be eligible 
for the study will then be randomized (1:1:1) to placebo or 1 of 2 active doses of NBI-98854 
(40 mg or 80 mg).  A 2-week supply of study drug will be dispensed.  Study drug will be 
administered in a double-dummy fashion throughout the 8-week double-blind treatment period.  
Beginning on Day 1, study drug will be administered at home once daily in the morning with a 
standard breakfast through Week 8.  The NBI-98854 80 mg dose will be titrated in a blinded 
fashion (subjects will receive 40 mg for the first week followed by 80 mg). 
At any time, if the subject is unable to tolerate their current dose, the investigator may decrease 
the subject’s dose.  The investigator is allowed to reduce the subject’s dose only one time during 
the study.  Subjects who have had a dose reduction and are unable to tolerate the new dose will 
be discontinued from the study.  To maintain the study blind, subjects receiving 40 mg or 
placebo who have a dose reduction will continue to receive their current dose and subjects 
receiving 80 mg will be reduced to 40 mg. 
During the double-blind treatment period, subjects will return to the study center at 2-week 
intervals (end of Weeks 2, 4, 6, and 8) for study assessments and dispensing of study drug 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
9 
 
(Weeks 2, 4, and 6 only).  All subjects who have completed the 8-week treatment period will 
enter a 2-week follow-up period with a follow-up visit at Week 10 (or early termination).   
Efficacy assessments for TS symptomatology include the Total Tic Score (TTS) from the Yale 
Global Tic Severity Scale (YGTSS) as the primary efficacy variable, and the YGTSS 
Impairment and Global Tic Severity scores, the Rush Video-Based Tic Rating Scale (RTRS), the 
Premonitory Urge for Tics Scale (PUTS), the Clinical Global Impression of Change-Tourette 
Syndrome (CGI-TS)-Improvement scale, and the Clinical Global Impression of Tics (CGI-
Tics)-Severity scale as secondary efficacy variables.  The YGTSS, RTRS, and PUTS will be 
administered at screening, on Day -1 (the day before dosing), during the double-blind treatment 
period (Weeks 2, 4, 6, and 8), and at the follow-up visit (Week 10) or early termination.  Note 
that all efficacy analyses for YGTSS-related variables are based on the certified site rater scores.  
Computer-generated tandem scores are also collected in the study database and will be presented 
in data listings only.    
The CGI-Tics-Severity will be evaluated at screening and Day -1 (baseline), and then both the 
CGI-Tics-Severity and CGI-TS-Improvement scales will be administered at Weeks 2, 4, 6, and 8 
and at the follow-up visit (Week 10) or early termination. 
Safety assessments will also be collected at scheduled times throughout the study, including 
adverse event (AE) monitoring, clinical laboratory tests (hematology, clinical chemistry, and 
urinalysis), vital sign measurements, physical examinations (including weight), 
electrocardiograms (ECGs), Columbia Suicide Severity Rating Scale (C-SSRS), Extrapyramidal 
Symptom Rating Scale-Abbreviated (ESRS-A; note that this assessment was added in study 
protocol amendment 3 and therefore, is not available for all subjects at all visits), Structured 
Interview Guide for the Hamilton Depression Rating Scale, 17-Item (SIGH-D-17), and the Yale-
Brown Obsessive-Compulsive Scale (Y-BOCS). 
Blood samples for plasma drug concentration and metabolite analyses will be collected during 
the treatment period (end of Weeks 2, 4, 6, and 8), and at the follow-up visit (Week 10) or early 
termination). 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
10 
 
3. 
STATISTICAL ANALYSES 
All analyses described in this plan are considered a priori analyses in that they have been defined 
prior to locking the study database. Analyses defined subsequent to locking the database will be 
considered post hoc analyses and will be applied as exploratory methodology. Any post hoc 
analyses will be clearly identified in the clinical study report. 
3.1. 
General Statistical Procedures 
Descriptive and inferential statistical methods will be used to summarize the data from this 
study.  The term “descriptive statistics” refers to the number of subjects (n), mean, median, 
standard deviation (SD), standard error of the mean (SEM), minimum, and maximum for 
continuous variables; and refers to the number and/or percentage of subjects (or events) for 
categorical variables.  The term “inferential statistics” refers to hypothesis tests which will be 
performed to assess differences between each NBI-98854 treatment (dose) group and the placebo 
group for selected efficacy variables.  All hypothesis tests will be tests of the null hypothesis of 
no difference between the treatment groups being compared versus the two-sided alternative 
hypothesis that there is a difference.   
The primary efficacy endpoint in this study is the YGTSS TTS mean change from baseline (Day 
-1) to Week 8 based on the certified site rater scores.  Inferential statistics will be calculated for 
this endpoint as well as for secondary and exploratory efficacy endpoints. Two-sided p-values 
will be reported for all hypothesis tests; however, interpretation of the p-values for the primary 
and key secondary efficacy endpoints will be based on a procedure to control for multiple 
comparisons which is described in Section 3.15.4. 
A comprehensive set of data listings including all randomized subjects will be provided.  These 
listings will include both measured and derived values.  Observations in data listings will 
typically be sorted by subject and timepoint (if applicable). 
The derived variable “study day” is used in a number of calculations for data summaries and 
listings.  This variable is calculated as the number of days after a subject’s Day -1 visit.  Study 
Day 1, then, is the day after the Day -1 visit. 
Summary statistics will be presented using a significant figure rule: the median, minimum, and 
maximum will have the same number of significant figures as the data; the mean will have one 
more significant figure than the data being summarized; the SD and SEM will have the same 
number of significant figures as the mean; and the sample size (N) will be reported as an integer.  
This rule may be modified if warranted, based on practical considerations. 
All analyses, tables, figures, and listings will be generated using SAS® software (version 9.3 or 
later), unless stated otherwise. 
3.2. 
Sample Size Calculation 
The protocol-specified sample size of 30 subjects per treatment group is based on a power 
calculation for the TTS change from baseline using a two-sample t-test with a two-sided Type I 
error of 0.05.  This sample size provides approximately 80% power to detect an effect size of 
0.75 and approximately 90% power to detect an effect size of 0.85.  Note that the effect size is 
defined as the mean difference between an NBI-98854 treatment group and the placebo group 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
11 
divided by the common SD (eg, a mean difference of 8 divided by an SD of 10 yields an effect 
size of 0.8).   
Standard deviations reported in the literature for TS studies evaluating changes in the TTS (with 
or without placebo controls) have generally been in the range of 7.5 to 9.5, and in placebo-
controlled studies, mean differences between active and placebo arms have been in the range of 
5 to 9 (Jankovic et al., 2010; Yoo et al., 2013; ClinicalTrials.gov NCT01727700).  The effect 
sizes of 0.75 and 0.85 mentioned in the above paragraph are representative of effect sizes seen in 
these published reports. 
3.3. 
Pooling of Sites 
Approximately 40 study centers are expected to participate in the study.  With the exception of 
the summary of subject enrollment by site, study sites will be pooled in all analyses, tables, and 
figures, since the majority of sites in this study are of a relatively small size, with fewer than five 
subjects expected to be enrolled.  In addition, study site will not be included as a factor in any 
statistical models. 
3.4. 
Handling of Early Termination Visit Data 
An early termination (ET) visit occurs when a subject withdraws from the study prior to 
completing the scheduled Week 10 visit.  An ET visit will be mapped to the next scheduled study 
visit if it occurs within 7 days prior to and 6 days after the expected study day of the next 
scheduled visit (with the requirement that the scheduled visit prior to the ET visit was actually 
completed by the subject).  An ET visit at Day 63 or later will be mapped to the Week 10 visit.  
Early termination visit data which are not mapped to a scheduled visit will be displayed in 
applicable by-subject data listings but not included in by-visit analyses and summaries.     
Table 1 displays the allowable study day range for each scheduled visit for ET visit mapping 
purposes. 
Table 1: 
Allowable Study Day Range for Early Termination Visit Mapping 
Scheduled Visit 
Target Study Day 
Time Interval 
(Study Day Range) 
Week 2 
14 
7-20
Week 4 
28 
21-34
Week 6 
42 
35-48
Week 8 
56 
49-62
Week 10 
70 
>62
3.5. 
Handling of Missing Data 
Missing values for outcome measures will not be replaced with imputed values except as noted 
above for the ET visit data mapped to a scheduled visit for summary and analysis purposes.  One 
exception to this is the imputation of missing values for the sensitivity analyses that will be 
performed in conjunction with the primary efficacy endpoint analysis as described in 
Section 3.15.5. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
12 
 
Derived scale total scores (eg, the YGTSS TTS score), which are calculated as the sum of the 
scores of the individual scale items, will be set equal to missing if any of the individual scale 
item scores are missing.    
Special rules for handling missing and incomplete dates are described below. 
3.5.1. 
Missing and incomplete dates 
Missing and incomplete (“partial”) dates for AEs and concomitant medications will be imputed 
only for the purpose of estimating the date of the event or medication usage in relationship to 
study treatment; however, all data listings will display the original dates as reported in the 
database.     
The imputation rules for AE start dates are as follows: 
 If the date is completely missing, the date will be imputed as the date of the first dose of 
study drug following randomization on Day -1; 
 If only the day component is missing from the date, the date will be imputed as the date 
of the first dose of study drug if the date is in the same month and year as the first dose of  
study drug; otherwise, the missing day component will be imputed as the first day of the 
month; 
 If both the day and month components are missing from the date, the date will be 
imputed as the date of the first dose of study drug if the date is in the same year as the 
first dose; otherwise, the missing components will be imputed as 01 January; 
 If any of the above imputations result in a start date that is later than an existing complete 
(not imputed) end date for the event, the start date will be set equal to the end date. 
The imputation rules for concomitant medication start dates are as follows: 
 If the date is completely missing, the date will be imputed as 01 January in the year of the 
subject’s screening vital signs assessment; 
 If only the day component is missing from the date, the date will be imputed as the date 
of  the first dose of study drug if the date is in the same month and year as the first dose 
of study drug; otherwise, the missing day component will be imputed as the first day of 
the month; 
 If both the day and month components are missing from the date, the date will be 
imputed as the date of the first dose of study drug if the date is in the same year as the 
first dose; otherwise, the missing components will be imputed as 01 January; 
 If any of the above imputations result in a start date which is later than an existing 
complete (not imputed) medication stop date, the start date will be set equal to the stop 
date. 
3.6. 
Coding Dictionary 
Medical history and AEs will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA, version 12.0).  Prior and concomitant medications will be coded using the World 
Health Organization (WHO) Drug Dictionary. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
13 
3.7. 
Analysis Sets 
3.7.1. 
Definition of Analysis Sets 
Three analysis sets will be defined for this study.   
The safety analysis set will include all subjects who are randomized to a treatment group and 
dispensed study drug, with the following two exclusions: (a) subjects who withdraw from the 
study and return all previously dispensed study drug with all doses present, and (b) subjects who 
have no postbaseline safety data collected. The safety analysis set will be used for all summaries 
of safety data (eg, AEs and clinical laboratory data) and pharmacokinetic plasma concentration 
data.  Subjects who are dispensed the incorrect treatment at the time of randomization, and 
remain on the same incorrect treatment during the study will be assigned to the treatment 
actually received in all summary tables and figures.  Subjects who are dispensed a combination 
of correct and incorrect treatments during the study will be assigned to the randomized treatment 
in all summary tables and figures. 
The primary efficacy analysis set is the intent-to-treat (ITT) analysis set, which will include all 
subjects in the safety analysis set who have at least one post-randomization TTS value reported 
at a scheduled visit or mapped ET visit during the 8-week treatment period.  The ITT analysis set 
will be used for summaries and analyses of efficacy data.  Treatment group assignment for all 
summaries and analyses using the ITT analysis set will be based on the randomization schedule. 
The per-protocol (PP) analysis set will include all subjects in the ITT analysis set who have a 
TTS value for the Week 8 visit (including an ET visit mapped to Week 8), have no efficacy-
related important protocol deviations (IPDs; described in Section 3.9) and, for subjects in the 
NBI-98854 treatment groups, have a detectable plasma level of NBI-98854 at the Week 8 visit, a 
measure of treatment adherence. The PP analysis set will be used for supportive summaries and 
analyses of the efficacy data.  Treatment group assignment for the PP analysis set will follow the 
rules described above for the safety analysis set.   
3.7.2. 
Summary of Analysis Sets 
A summary of the number and percentage of subjects included in (and excluded from, as 
applicable) each analysis set will be provided for each treatment group and overall (for all 
randomized subjects).  The number and percentage of subjects excluded from each analysis set 
by reason for exclusion will also be provided. 
3.7.3. 
Application of Analysis Sets 
Summaries of subject disposition, enrollment by study site, analysis set inclusion/exclusion 
status, and IPDs will include all randomized subjects.  All other summaries by analysis set are 
identified in Table 2. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
14 
Table 2: 
Data Summaries by Analysis Set 
Data Summary/Analysis 
Analysis Set 
Safety
ITT
PP
Demographics
X
X
X
Baseline subject characteristics 
X 
X 
X 
Medical history 
X 
Study drug dosing (including dose reductions) 
X 
X 
Pharmacokinetic plasma concentration data 
X 
YGTSS
X
X
RTRS
X
X
PUTS
X
X
CGI-Tics-Severity
X
X
CGI-TS-Improvement
X
X
Adverse events 
X 
C-SSRS
X
ESRS-A
X
SIGH-D-17
X
Y-BOCS
X
Vital signs 
X 
Physical examination 
X 
Weight
X
ECGs
X
Clinical laboratory data 
X 
Prior and Concomitant medications 
X 
3.8. 
Subject Randomization and Disposition 
The summary of subject randomization and disposition will display the number of subjects who 
were randomized to each treatment group, completed the 8-week treatment period (defined as 
having completed a scheduled Week 8 visit [does not include ET visits mapped to Week 8]), and 
completed the study (defined as having completed a scheduled Week 10 visit [does not include 
ET visits mapped to Week 10]).  The number of subjects who did not complete the study will be 
displayed both overall and by reason for discontinuation.   
This summary table will also include an “all subjects” column.  
A separate summary of randomization by study site will be presented.  This summary will 
display the number of subjects randomized to each treatment group at each site.  An “all 
subjects” column will be included in the table. 
An additional table will display the number of subjects in each treatment group who completed 
each study visit (screening through Week 10; including mapped ET visits).  This table will also 
include an “all subjects” column and will be based on the safety analysis set. 
3.9. 
Important Protocol Deviations 
Important protocol deviations (IPDs) are protocol deviations that might significantly affect the 
completeness, accuracy and/or reliability of the study data or that might significantly affect a 
subject’s rights, safety, or well-being.  An assessment of IPDs will be performed by a committee 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
15 
composed of NBI Clinical Development project team members prior to database lock.  Important 
protocol deviations may include, but are not limited to the following:   

Failure to obtain informed consent from the subject prior to performing any study
procedures

Deviations from key inclusion/exclusion criteria

Use of prohibited concomitant medications

Error in drug dispensing which results in a subject not receiving intended randomized
treatment

Significant deviation from protocol-specified dosing regimen

Significant deviations in YGTSS administration
A summary of the number and percentage of subjects with IPDs by deviation category for each 
treatment group will be provided for all randomized subjects.  All protocol deviations captured in 
the clinical study database will be included in the data listings. 
3.10. 
Demographic Data and Baseline Characteristics 
Demographic data (age, gender, race, and ethnicity) and baseline characteristics (age at TS 
diagnosis, baseline value of TTS [certified site rater scores], height, weight, body mass index 
[BMI], and CYP2D6 genotype status) will be summarized using descriptive statistics and 
frequency tables.  These data will be summarized by treatment group with an additional “all 
subjects” column in the summary table. 
3.11. 
Medical History 
Medical history will be summarized in frequency tables (number and percentage of subjects) by 
MedDRA System Organ Class (SOC) and Preferred Term (PT) for each treatment group. 
3.12. 
Study Drug Dosing Compliance 
Study drug dosing compliance is calculated as the ratio of the estimated number of doses taken 
by a subject to the expected number of doses that should have been taken (given the length of 
time the subject participated in the study treatment period), and is expressed as a percentage.  A 
subject is classified as being compliant with study drug administration if their calculated value is 
80% or greater.  The number and percentage of subjects in each treatment group who are 
compliant will be presented for Weeks 2, 4, 6, and 8, and for the full treatment period.  
The number of doses taken by each subject between two consecutive visits will be estimated by 
calculating the difference between the number of capsules dispensed at the first visit and the 
number of capsules returned at the subsequent visit (note that the number of doses taken is equal 
to the number of capsules taken divided by 2, as each dose is to be taken as 2 capsules of study 
drug per study protocol).  If an ET visit occurs between scheduled visits, the ET visit data will be 
used in the calculation. If a subject fails to return the study drug kit dispensed at the previous 
visit, it will be assumed that the number of doses taken by the subject is equal to the number of 
days between visits (inclusive of the day of the second visit; not to exceed the number of doses 
dispensed), as subjects are expected to take one dose per day.  If a subject is lost to follow-up 
between scheduled visits, their dosing data will be limited to the last visit at which they were 
present. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
16 
The estimated number of doses taken by a subject across all visits during the treatment period is 
calculated as the sum of the number of doses taken between each consecutive pair of visits 
during the treatment period. 
The expected number of doses that should have been taken by a subject between or across visits 
is based on the expected number of days the subject should have dosed with study drug during 
the interval of interest, which in turn is based on the duration of the subject’s study participation 
during the interval (which may be shorter, for example, if the subject withdraws from the study).   
The expected number of days of dosing (and hence, expected number of doses that should have 
been taken) is calculated as the difference between the visit date of the second of the two visits 
and the study drug kit dispense date at the first of the two visits.  Note that the expected number 
of days of dosing cannot exceed the total number of doses actually dispensed (each study drug 
kit in this study contains 17 doses of study drug).  If an ET visit occurs between scheduled visits, 
the ET visit date will be used in the calculation.  If a subject is lost to follow-up between 
scheduled visits, they will be excluded from the compliance calculations for all visits occurring 
after the last visit at which they were present.  If a subject has a missed visit but has previously 
been dispensed an extra study drug kit that would have been dispensed at the missed visit, they 
will be excluded from the compliance calculations for all visits beginning with the missed visit, 
but will be included in the overall treatment period calculations described in the next paragraph. 
The dosing compliance calculation across all visits during the study treatment period will follow 
the logic described above, with the expected number of days of dosing being equal to the 
difference between the Week 8 (or ET) visit date and the study drug kit dispense date for the 
Day -1 visit. The estimated number of doses taken by a subject across all visits during the study 
is calculated as the sum of the number of doses taken between each consecutive pair of visits 
during the treatment period.  If a subject is lost to follow-up prior to Week 8, their dosing 
compliance will be based on the last study visit at which they were present.   
3.13. 
Dose Reduction Summary 
The dose reduction summary will present the number and percentage of subjects with a dose 
reduction for each treatment group at Weeks 2, 4, and 6. Dose reductions at unscheduled visits 
prior to Week 6 will be included in the summary for the next scheduled visit (ie, Week 2, 4, or 
6).  Dose reductions at unscheduled visits after Week 6 will be summarized as “After Week 6” in 
the table. The table will also include the total number and percentage of subjects with a dose 
reduction at any time during the study treatment period. Note that this summary includes all 
reports of dose reductions, including those for the placebo and the NBI-98854 40 mg dose 
treatment groups (which are not true dose reductions).  
3.14. 
Pharmacokinetic Data 
The plasma concentrations of NBI-98854 and its active metabolite NBI-98782 will be 
summarized with descriptive statistics by visit (Weeks 2, 4, 6, 8, and 10) and the most recent 
NBI-98854 dose received by a subject prior to that visit (this is due to the possibility of a subject 
having a dose reduction from 80 mg to 40 mg).  Note that a subject’s treatment group for the 
Week 10 visit summary will reflect the last dose the subject received during the study treatment 
period.   


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
17 
 
This summary will also be generated separately for CYP2D6 poor metabolizers vs. non-poor 
metabolizers.   
Concentrations below the lower limit of quantification (BLQ) will be set equal to zero for all 
plasma concentration summaries. The lower limits of quantification are as follows:  (a) NBI-
98854: 1.00 ng/mL and (b) NBI-98782: 0.100 ng/mL. 
The following additional descriptive statistics will be included in the plasma concentration 
summary tables:  (a) the number of subjects with plasma concentration values greater than or 
equal to the lower limit of quantification, (b) the geometric mean, and (c) the geometric 
coefficient of variation (%). 
Plasma concentrations of each PK analyte will be summarized with box plots by NBI-98854 
dose level at each visit. 
3.15. 
Efficacy Data 
3.15.1. 
Efficacy Endpoints 
The efficacy endpoints for this study are described in detail in the follow sections of this SAP.  
An overall summary of the efficacy endpoints is presented below in Table 3. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
18 
 
Table 3: 
Efficacy Endpoints and Classification 
Efficacy Endpoint 
Endpoint Classification  
YGTSS Total Tic Score (TTS) mean change from baseline to Week 8 
Primary 
CGI-TS-Improvement mean score at Week 8 
Key secondary 
Percentage of subjects classified as YGTSS TTS responders at Week 8 
Secondary 
YGTSS Impairment score mean change from baseline to Week 8 
Secondary 
YGTSS Global Tic Severity score mean change from baseline to Week 8 
Secondary 
Rush Video-based Tic Rating Scale (RTRS) total score mean change from 
baseline to Week 8 
Secondary 
Premonitory Urge for Tics Scale (PUTS) total score mean change from 
baseline to Week 8 
Secondary 
CGI-Tics-Severity score mean change from baseline to Week 8 
Secondary 
Percentage of subjects classified as CGI-TS-Improvement responders at 
Week 8  
Secondary 
YGTSS Total Tic Score (TTS) mean change from baseline to Weeks 2, 4, 
and 6 
Exploratory 
CGI-TS-Improvement mean score at Weeks 2, 4, and 6 
Exploratory 
Percentage of subjects classified as YGTSS TTS responders at Weeks 2, 4, 
and 6 
Exploratory 
YGTSS Impairment score mean change from baseline to Weeks 2, 4, and 6
Exploratory 
YGTSS Global Tic Severity score mean change from baseline to Weeks 2, 
4, and 6 
Exploratory 
Rush Video-based Tic Rating Scale (RTRS) total score mean change from 
baseline to Weeks 2, 4, and 6 
Exploratory 
Premonitory Urge for Tics Scale (PUTS) total score mean change from 
baseline to Weeks 2, 4, and 6 
Exploratory 
CGI-Tics-Severity score mean change from baseline to Weeks 2, 4, and 6 
Exploratory 
Percentage of subjects classified as CGI-TS-Improvement responders at 
Weeks 2, 4, and 6 
Exploratory 
3.15.2. 
Primary Efficacy Endpoint 
The primary efficacy endpoint for this study is the mean change from baseline (Day -1) to Week 
8 in the YGTSS TTS (Total Tic Score) based on the certified site rater scores.  Mean changes 
from baseline to Weeks 2, 4, and 6 are exploratory efficacy endpoints. 
The TTS is defined as the sum of the YGTSS motor tic severity score and phonic (vocal) tic 
severity score.  The motor tic severity score is calculated as the sum of the scores for the 5 motor 
tic items (number, frequency, intensity, complexity, and interference).  The score for each item 
can range from 0 to 5, for a maximum total score of 25.  The vocal (phonic) tic severity score is 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
19 
 
calculated similarly.  If any one of the 5 items for the motor or vocal tic severity score is not 
scored (ie, has a missing value), the associated severity score will be set equal to missing.   If any 
of these items has a missing value at a given subject visit, the TTS value for the subject visit will 
be set equal to missing as well.  The TTS value can range from 0 to 50. 
Descriptive statistics will be presented by treatment group for the TTS observed values (ie, the 
raw data) and changes from baseline (Day -1) at each visit from screening through Week 10.  
Descriptive statistics will be presented for both the ITT and the PP analysis sets.   
The primary efficacy endpoint method of analysis will be a mixed-effect model repeated 
measures (MMRM) analysis, which includes the changes from baseline at Weeks 2, 4, 6, and 8, 
and is based on the ITT analysis set.  The model will include the baseline TTS as a covariate, and 
treatment group, visit (Week 2, 4, 6, or 8), treatment group by visit interaction, and baseline 
covariate by visit interaction as fixed effects.  Subject will be included as a random effect.  Study 
site will not be included in the model, as there is a large number of sites, with most sites 
enrolling a small number of subjects.  
Treatment group comparisons for each NBI-98854 treatment group vs. placebo at each visit (ie, 
Weeks 2, 4, 6, and 8) will be performed by constructing linear contrasts (or equivalent program 
coding) for differences between treatment group least-squares (LS) means.  Nominal two-sided 
p-values for testing the significance of these differences and associated 95% confidence intervals 
will be reported in summary tables; however, interpretation of the p-values for the two active 
treatment group comparisons to placebo at Week 8 will be based on the fixed-sequence testing 
procedure described below in Section 3.15.4.  
A supportive analysis using the MMRM model will be performed with the PP analysis set. 
The MMRM analysis will be implemented with the PROC MIXED procedure of SAS®, using 
the restricted maximum likelihood method, an unstructured within-subject covariance matrix, 
and denominator degrees of freedom from the Kenward-Roger method. In the event that 
convergence is not obtained with the unstructured covariance matrix, a Toeplitz covariance 
structure will be used. 
An additional supportive analysis of the TTS change from baseline to Week 8 will be performed 
using an ANCOVA model.  The ANCOVA model will include the baseline TTS as a covariate 
and treatment group as a fixed effect.  This analysis will be performed using both the ITT and PP 
analysis sets. 
Mean (±SEM) values of the TTS values at each visit (Day -1 through Week 10) will be 
summarized in line graphs by treatment group.  Similar graphs will be presented for the changes 
from baseline (Day -1).  These graphs will be based on the ITT analysis set. 
The LS means (±SEM) from the MMRM analysis will be summarized in line graphs by 
treatment group for both the ITT and PP analysis sets.   
An additional graph will be presented for the TTS changes from baseline to Week 8.  This will 
be a display of the empirical distribution function for each treatment group, and will be based on 
the ITT analysis set. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
20 
 
3.15.3. 
Key Secondary Efficacy Endpoint 
The key secondary efficacy endpoint for this study is the CGI-TS-Improvement mean score at 
Week 8.  Mean scores at Weeks 2, 4, and 6 are exploratory efficacy endpoints. 
Each of the CGI-TS-Improvement response categories will be assigned a numerical score as 
follows: 
Very much improved = 1 
Much improved = 2 
Minimally improved = 3 
Not changed = 4 
Minimally worse = 5 
Much worse = 6 
Very much worse = 7 
Descriptive statistics (including both categorical variable statistics [using response categories] 
and continuous variable statistics [using numerical scores]) will be presented by treatment group 
for the CGI-TS-Improvement data at each visit from Week 2 through Week 10.  Descriptive 
statistics will be presented for both the ITT and the PP analysis sets.  
An analysis of the CGI-TS-Improvement numerical scores at Week 8 will be performed using an 
ANOVA model which includes treatment group as a fixed effect.  The Week 2, 4, and 6 data will 
be analyzed also using the same ANOVA model.   Nominal two-sided p-values for testing the 
significance of the mean difference between each NBI-98854 treatment group and the placebo 
group and associated 95% confidence intervals will be reported in summary tables; however, 
interpretation of the p-values for the two active treatment group comparisons to placebo at Week 
8 will be based on the fixed-sequence testing procedure described below in Section 3.15.4. 
Supportive analyses of the CGI-TS-Improvement numerical scores will be performed using an 
ANOVA at each visit based on the PP analysis set. 
Mean (±SEM) values of the CGI-TS-Improvement numerical scores at each visit will be 
summarized in line graphs by treatment group.  These graphs will be based on the ITT analysis 
set. 
The LS means (±SEM) from the ANOVA analyses of the CGI-TS-Improvement numerical 
scores at Weeks 2 through 8 will be summarized in line graphs by treatment group for both the 
ITT and PP analysis sets. 
3.15.4. 
Fixed-Sequence Testing Procedure to Control for Multiple Comparisons 
A fixed-sequence testing procedure will be followed for the primary and key secondary efficacy 
endpoint analyses in order to control for multiple comparisons (ie, comparing each of the two 
NBI-98854 doses to placebo for each of the two endpoints).  The fixed-sequence testing 
procedure will consist of performing the hypothesis tests in the following pre-specified order: 
 Week 8 TTS mean change from baseline:  NBI-98854 80 mg treatment group vs. placebo 
treatment group 
 Week 8 TTS mean change from baseline:  NBI-98854 40 mg treatment group vs. placebo 
treatment group 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
21 
 
 Week 8 CGI-TS-Improvement mean score:  NBI-98854 80 mg treatment group vs. 
placebo treatment group 
 Week 8 CGI-TS-Improvement mean score:  NBI-98854 40 mg treatment group vs. 
placebo treatment group 
In order for a test result in the above list to be considered statistically significant, all of the test 
results higher in the list must be significant at the 0.05 level of significance. 
3.15.5. 
Sensitivity Analyses for Primary Efficacy Endpoint 
An underlying assumption of the MMRM analysis is that missing data are considered to be 
missing at random (MAR).  In addition to assessing the number of subjects who prematurely 
discontinue from the study prior to Week 8 along with the reasons for premature study 
discontinuation, three sensitivity analyses of the TTS changes from baseline will be performed to 
assess the impact of deviations from the assumption that the missing TTS data are MAR.  These 
analyses, described below, are based on the ITT analysis set. 
Tipping Point - Sensitivity Analysis #1 
Step 1 of Sensitivity Analysis #1 (Imputation of Missing Data) 
The initial step will be to impute missing TTS values at Weeks 2 through 8 using the SAS® 
procedure PROC MI.   The data will first be examined to determine if the pattern of missing data 
is monotone or non-monotone across visits from Day -1 (baseline) through Week 8.  If the 
pattern of missing data is monotone (which will be the case if the missingness is purely due to 
dropouts) the regression method of PROC MI will be used to impute the missing data. If the 
pattern of missing data is non-monotone, the Markov chain Monte Carlo (MCMC) method of 
PROC MI will be used to create a monotone data set, using default system values for the 
parameters CHAIN, NBITER and NITER (along with IMPUTE=MONOTONE).  This data set 
can then be analyzed using the regression method of PROC MI.  In either case, 100 imputed data 
sets will be generated using a random number generator seed value of 1470681.   The SAS® 
statements (or equivalent) provided below will be used for the imputation of missing data.  Note 
that “Treat” represents randomized treatment group (placebo, NBI-98854 40 mg, or NBI-98854 
80 mg), “Baseline” is the Day -1 TTS value, and Week2, Week4, Week6, and Week8 are the 
TTS values at Weeks 2, 4, 6, and 8, respectively. 
PROC MI NIMPUTE=100 SEED=1470681 MINIMUM=0 MAXIMUM=50 
OUT=Imputed; 
CLASS Treat; 
MONOTONE REGRESSION; 
VAR Treat Baseline Week2 Week4 Week6 Week8; 
Step 2 of Sensitivity Analysis #1 (Creation of Additional Data Sets with NBI-98854 Treatment 
Group Imputed TTS Scores Made Worse in a Step-Wise Fashion)   
The sensitivity analysis itself will involve the creation of additional data sets based on the fully 
imputed data sets created in Step 1, with a step-wise “worsening-score” algorithm applied to the 
NBI-98854 treatment groups, but not to the placebo treatment group.  Since the primary endpoint 
is the TTS mean change from baseline at Week 8, the scores at Weeks 2, 4, and 6, which were 
used for missing data imputation purposes, will not be used in any subsequent calculations or 
analyses.  Therefore, the worsening-score algorithm will be applied only to the NBI-98854 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
22 
 
treatment group imputed Week 8 TTS values (also note that the method of analysis for the 
imputed data sets described below in Step 3 is an ANCOVA of the Week 8 TTS changes from 
baseline).  
The worsening-score algorithm will involve increasing (or “worsening”) the imputed Week 8 
TTS values in the two NBI-98854 treatment groups by a percentage of the imputed value in a 
pre-specified, step-wise fashion.  Imputed Week 8 TTS values in the placebo treatment group 
will not be made worse in this algorithm and will remain at the initially imputed values. 
The initial percentage value to be applied is 10%.  This will be increased in fixed increments of 
10% until the p-value for the comparison of the NBI-98854 80 mg treatment group to the 
placebo treatment group (obtained as described below in Step 3 from PROC MIANALYZE 
applied to the results of 100 ANCOVAs for each imputed data set) exceeds the nominal 0.05 
level of significance.  Note that the maximum possible value for the TTS is 50; therefore an 
imputed Week 8 TTS value adjusted according to this algorithm cannot exceed the value of 50. 
This sensitivity analysis represents a tipping point analysis based on “delta adjustments,” which 
is a commonly used approach to assess the impact of missing data in clinical trials (O’Kelly and 
Ratitch, 2014). 
Step 3 of Sensitivity Analysis #1 
The TTS changes from baseline to Week 8 will be calculated for each of the imputed data sets 
from the original PROC MI output and for the additional sets of data created according to the 
worsened-score algorithm described above in Step 2.  The imputed data sets will be analyzed 
using the ANCOVA model specified above in Section 3.15.2, using either PROC MIXED or 
PROC GLM.     
PROC MIANALYZE will then be used to combine results from the 100 ANCOVAs for the 
imputed data sets to provide the following statistics: 
 LS mean for each treatment group 
 LS mean difference between each NBI-98854 treatment group and the placebo treatment 
group, along with the corresponding two-sided 95% confidence intervals and p-values 
Jump to Reference (J2R) - Sensitivity Analysis #2 
The J2R method is based on the concept that missing values for subjects in the NBI-98854 
treatment groups who drop out prior to the Week 8 visit will tend to be similar to values for 
subjects in the reference (placebo) group who have similar baseline characteristics.  This is 
plausible under the assumption that treatment with NBI-98854 offers symptomatic, and not 
disease-modifying treatment, and as such, subjects who stop taking active study drug will no 
longer benefit from its therapeutic effect, but will still be subject to any placebo (or study 
participation related) effects. 
The J2R analysis will be implemented using the SAS® procedures PROC MI and PROC 
MIANALYZE.  If the pattern of missing data across study visits during the treatment period is 
non-monotone, a monotone data set will be created using PROC MI with the MCMC method, a 
seed value of 1470681, and system default values for the parameters CHAIN, NBITER, and 
NITER (along with IMPUTE=MONOTONE).  The number of imputed data sets created in this 
step will be 100. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
23 
 
The actual J2R imputation will follow the sequential model approach described in Chapter 7.4.3 
of O’Kelly and Ratitch (2014).  With this approach, the placebo treatment group data are used to 
impute missing values for the NBI-98854 treatment groups, one visit at a time in a sequential 
fashion.  At each visit imputation step, PROC MI with the same seed specified in the preceding 
paragraph (and 100 imputed data sets) will be implemented, using the monotone regression 
method with the baseline TTS as an explanatory variable.  Note that missing data values in the 
placebo treatment group are imputed under the MAR assumption (using PROC MI with the 
monotone regression method), prior to imputing missing data values in the NBI-98854 treatment 
groups. 
The final step of this analysis will consist of performing an ANCOVA analysis of the TTS 
changes from baseline at Week 8 using the imputed data sets and then combining the results of 
these analyses using PROC MIANALYZE.   
Baseline Observation Carried Forward (BOCF) – Sensitivity Analysis #3 
The use of a BOCF analysis as a sensitivity analysis is described in a publication authored by Dr. 
Lisa LaVange of the FDA/CDER Office of Biostatistics (LaVange, 2014).  This analysis will be 
implemented by imputing missing Week 8 TTS values in all three treatment groups with the 
baseline values (ie, a subject’s missing Week 8 value will be set equal to their baseline value). 
The TTS changes from baseline at Week 8, including BOCF-imputed missing values for Week 8, 
will then be analyzed using the ANCOVA model, using either PROC MIXED or PROC GLM.  
As this is a single-imputation method, the use of PROC MI and PROC MIANALYZE is not 
required. 
3.15.6. 
Secondary Efficacy Endpoints 
3.15.6.1. YGTSS TTS Responder Analysis 
A TTS responder is defined, on a per-visit basis, as a subject whose TTS value is reduced by at 
least 30% from baseline (Day -1) at the specified postbaseline visit. The percentage of subjects 
classified as TTS responders will be summarized for each treatment group at Weeks 2, 4, 6, 8, 
and 10 for both the ITT and PP analysis sets.  
The percentage of subjects classified as TTS responders at Week 8 is a secondary efficacy 
endpoint.  An analysis comparing each NBI-98854 treatment group to the placebo treatment 
group will be performed for this endpoint with the ITT analysis set using the standard chi-square 
test.  A separate chi-square test will be performed for each treatment group comparison 
(NBI-98854 80 mg treatment group vs. placebo treatment group and NBI-98854 40 mg treatment 
group vs. placebo treatment group). 
A supportive analysis of the percentage of subjects classified as TTS responders at Week 8 will 
be performed using the PP analysis set. 
The percentages of subjects classified as TTS responders at Weeks 2, 4, and 6 are exploratory 
endpoints.  These endpoints will be analyzed using the chi-square test at each of these visits with 
both the ITT and PP analysis sets. 
Bar graphs displaying the percentage of subjects classified as TTS responders will be presented 
by treatment group for each study visit from Week 2 through Week 10 for the ITT and PP 
analysis sets. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
24 
 
3.15.6.2. YGTSS Impairment Score 
The YGTSS Impairment score can range in value from 0 to 50.  The YGTSS Impairment score 
mean change from baseline to Week 8 is a secondary efficacy endpoint.  Mean changes from 
baseline to Weeks 2, 4, and 6 are exploratory efficacy endpoints. 
Descriptive statistics will be presented by treatment group for the YGTSS Impairment score 
observed values (ie, the raw data) and changes from baseline (Day -1) at each visit from 
screening through Week 10.  Descriptive statistics will be presented for both the ITT and the PP 
analysis sets.   
The analysis of the YGTSS Impairment score changes from baseline at each visit from Week 2 
through Week 8 will be performed using a MMRM model similar to the model described in 
Section 3.15.2 for the TTS change from baseline, based on the ITT analysis set.  The covariate 
for this MMRM model will be the YGTSS Impairment score at baseline.  A supportive analysis 
of the YGTSS Impairment score changes from baseline will be performed using the PP analysis. 
Mean (±SEM) values of the YGTSS Impairment score at each visit (Day -1 through Week 10) 
will be summarized in line graphs by treatment group.  Similar graphs will be presented for the 
changes from baseline (Day -1).  These graphs will be based on the ITT analysis set. 
The LS means (±SEM) from the MMRM analysis of the YGTSS Impairment score changes from 
baseline will be summarized in line graphs by treatment group for both the ITT and PP analysis 
sets. 
3.15.6.3. YGTSS Global Tic Severity Score 
The YGTSS Global Tic Severity score is the sum of the TTS and the YGTSS Impairment score.  
The YGTSS Global Tic Severity score at a given subject visit will be set equal to missing if 
either of the TTS or Impairment scores are missing.  The YGTSS Global Tic Severity score 
value can range from 0 to 100.  
The YGTSS Global Tic Severity score mean change from baseline to Week 8 is a secondary 
efficacy endpoint.  Mean changes from baseline to Weeks 2, 4, and 6 are exploratory efficacy 
endpoints.  
Descriptive statistics will be presented by treatment group for the YGTSS Global Tic Severity 
score observed values (ie, the raw data) and changes from baseline (Day -1) at each visit from 
screening through Week 10.  Descriptive statistics will be presented for both the ITT and the PP 
analysis sets.   
An analysis of the YGTSS Global Tic Severity change-from-baseline scores at each visit from 
Week 2 through Week 8 will be performed using a MMRM model similar to the model described 
in Section 3.15.2 for the TTS change from baseline, based on the ITT analysis set.  The covariate 
for this MMRM model will be the YGTSS Global Tic Severity score at baseline.  A supportive 
analysis of the YGTSS Global Tic Severity scores will be performed using the PP analysis set. 
Mean (±SEM) values of the YGTSS Global Tic Severity score at each visit (Day -1 through 
Week 10) will be summarized in line graphs by treatment group.  Similar graphs will be 
presented for the changes from baseline (Day -1).  These graphs will be based on the ITT 
analysis set. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
25 
 
The LS means (±SEM) from the MMRM analysis of the YGTSS Global Tic Severity score 
changes from baseline will be summarized in line graphs by treatment group for both the ITT 
and PP analysis sets. 
3.15.6.4. Rush Video-based Tic Rating Scale (RTRS) 
The modified RTRS used in this study includes short video recordings to measure 5 tic variables:  
number of body areas affected, frequency of motor and phonic tics, and severity of motor and 
phonic tics. The RTRS videos for Day -1 and Week 8 (or final on-treatment visit for subjects 
who discontinue from the study prior to Week 8) will be reviewed and scored by a pair of 
blinded central raters using a consensus scoring process that is blinded to both treatment and visit 
sequence.  The summaries and analyses of the RTRS data, then, will be limited to the scores 
recorded for these two visits for each subject.  
The RTRS total score is calculated as the sum of the 5 domain scores (number of body areas 
affected, motor tic frequency, phonic tic frequency, severity of motor tics, and severity of phonic 
tics).  The score for each domain can range from 0 to 4, for a maximum possible total score of 
20.  If any one of the 5 domains is not scored (ie, has a missing value), the total score will be set 
equal to missing.  
The RTRS total score mean change from baseline to Week 8 (or final on-treatment visit if prior 
to Week 8) is a secondary efficacy endpoint. 
Descriptive statistics will be presented by treatment group for the RTRS total score observed 
values (ie, the raw data) at each visit and changes from baseline (Day -1).  Descriptive statistics 
will be presented for both the ITT and the PP analysis sets.   
An analysis of the RTRS total score changes from baseline to Week 8 (or final on-treatment visit 
if prior to Week 8) will be performed using an ANCOVA model similar to the model described 
in Section 3.15.2 for the TTS change from baseline.  The covariate for this analysis will be the 
RTRS total score at baseline.  A supportive analysis of the RTRS total scores will be performed 
using the PP analysis set. 
Mean (±SEM) values of the RTRS total score for each treatment group at each visit will be 
summarized in a bar graph.  A similar graph will be presented for the changes from baseline.  
These graphs will be based on the ITT analysis set. 
The LS means (±SEM) from the ANCOVA analysis of the RTRS total score changes from 
baseline to Week 8 (or final on-treatment visit if prior to Week 8) will be summarized in a bar 
graph by treatment group for both the ITT and PP analysis sets.   
3.15.6.5. Premonitory Urge for Tics Scale (PUTS) 
The PUTS consists of 9 items, each of which is scored on a 4-point scale (1=not at all true, 2=a 
little true, 3=pretty much true, 4=very much true).  The PUTS total score is calculated as the sum 
of the scores for the 9 items.  The maximum possible total score is 36.  If any one of the 9 items 
is not scored (ie, has a missing value), the PUTS total score will be set equal to missing. 
The PUTS total score mean change from baseline to Week 8 is a secondary efficacy endpoint.  
Mean changes from baseline to Weeks 2, 4, and 6 are exploratory efficacy endpoints.  


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
26 
 
Descriptive statistics will be presented by treatment group for the PUTS total score observed 
values (ie, the raw data) and changes from baseline (Day -1) at each visit from screening through 
Week 10.  Descriptive statistics will be presented for both the ITT and the PP analysis sets.   
An analysis of the PUTS total score changes from baseline at each visit from Week 2 through 
Week 8 will be performed using a MMRM model similar to the model described in Section 
3.15.2 for the TTS change from baseline.  The covariate for this MMRM analysis will be the 
PUTS total score at baseline.  A supportive analysis of the PUTS total scores will be performed 
using the PP analysis set. 
Mean (±SEM) values of the PUTS total score at each visit (Day -1 through Week 10) will be 
summarized in line graphs by treatment group.  Similar graphs will be presented for the changes 
from baseline.  These graphs will be based on the ITT analysis set. 
The LS means (±SEM) from the MMRM analysis of the PUTS total score changes from baseline 
to Weeks 2 through 8 will be summarized in line graphs by treatment group for both the ITT and 
PP analysis sets.   
3.15.6.6. CGI-Tics-Severity 
Each of the CGI-Tics-Severity response categories will be assigned a numerical score as follows: 
 Normal, not at all ill = 1 
 Borderline ill = 2 
 Mildly ill = 3 
 Moderately ill = 4 
 Markedly ill = 5 
 Severely ill = 6 
 Among the most extremely ill patient = 7 
The CGI-Tics-Severity numerical score mean change from baseline to Week 8 is a secondary 
efficacy endpoint.  Mean changes from baseline to Weeks 2, 4, and 6 are exploratory efficacy 
endpoints.  
Descriptive statistics (including both categorical variable statistics [using response categories] 
and continuous variable statistics [using numerical scores]) will be presented by treatment group 
for the CGI-Tics-Severity data at each visit from screening through Week 10.  Changes from 
baseline (Day -1) for the numerical scores will be summarized also.  Descriptive statistics will be 
presented for both the ITT and the PP analysis sets.  
An analysis of the CGI-Tics-Severity numerical score changes from baseline to each visit from 
Week 2 through Week 8 will be performed using a MMRM model similar to the model described 
in Section 3.15.2 for the TTS changes from baseline.  The covariate for this MMRM analysis 
will be the CGI-Tics-Severity numerical score at baseline.  A supportive analysis of the CGI-
Tics-Severity numerical scores will be performed using the PP analysis set. 
Mean (±SEM) values of the CGI-Tics-Severity numerical scores at each visit (Day -1 through 
Week 10) will be summarized in line graphs by treatment group.  Similar graphs will be 
presented for the changes from baseline.  These graphs will be based on the ITT analysis set. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
27 
 
The LS means (±SEM) from the MMRM analysis of the CGI-Tic-Severity numerical score 
changes from baseline to Weeks 2 through 8 will be summarized in line graphs by treatment 
group for both the ITT and PP analysis sets.   
3.15.6.7. CGI-TS-Improvement Responder Analysis 
A subject is classified as a CGI-TS-Improvement responder at a given visit if their CGI-TS-
Improvement score is either a “1” (“very much improved”) or a “2” (“much improved”) at the 
visit.  
The percentage of subjects classified as CGI-TS-Improvement responders at Week 8 is a 
secondary efficacy endpoint.  The percentages of responders at Weeks 2, 4, and 6 are exploratory 
efficacy endpoints. 
The number and percentage of responders will be summarized for each treatment group at Weeks 
2, 4, 6, 8, and 10.  The CGI-TS-Improvement responder summary statistics will be presented for 
both the ITT and the PP analysis sets.   
An analysis comparing each NBI-98854 treatment group to the placebo treatment group will be 
performed for the percentage of subjects classified as CGI-TS-Improvement responders at each of 
Weeks 2 through 8 using the standard chi-square test with the ITT analysis set.  A separate chi-
square test will be performed for each NBI-98854 treatment group comparison to placebo for each 
visit.  
A supportive analysis of the percentage of subjects classified as CGI-TS-Improvement responders at 
Weeks 2 through 8 will be performed using the PP analysis set. 
Bar graphs displaying the percentage of subjects classified as CGI-TS-Improvement responders 
at Weeks 2 through 10 will be presented by treatment group for the ITT and the PP analysis sets. 
3.16. 
Safety Data 
3.16.1. 
Adverse Events 
A treatment-emergent adverse event (TEAE) is any reaction, side effect, or other untoward 
event, regardless of relationship to study drug, that is newly reported or considered a worsening 
or change in nature, severity, or frequency of conditions present at the start of the study which 
occurs any time after first dose of study drug. 
TEAEs, categorized by MedDRA (Version 12.0) system organ class (SOC) and preferred term 
(PT), will be summarized by treatment group in frequency tables.  Each table will also include a 
separate column for all NBI-98854 treated subjects (ie, excluding placebo subjects).  Unless 
stated otherwise, the frequency tables will include the number of events reported, and the number 
and percentage of unique subjects experiencing each event one or more times during the study.  
SOCs will be displayed in order of decreasing frequency (number of subjects with TEAEs in the 
SOC based on the “all NBI-98854 treated subjects” column), and within each SOC, PTs will be 
displayed in a similar fashion in order of decreasing frequency of subjects with TEAEs in the PT 
based on the “all NBI-98854 treated subjects” column.   
Two versions of the primary TEAE frequency table will be presented:  (a) the first version as  
described above which includes both SOC and PT, with each sorted in decreasing frequency 
based on the “all NBI-98854 treated subjects” column, and (b) a second version which does not 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
28 
 
include SOCs but does include PTs sorted in decreasing frequency based on the “all NBI-98854 
treated subjects” column. 
Frequency tables will be presented including only TEAEs considered to be possibly or definitely 
related to study drug and categorizing TEAEs according to the maximum intensity reported for a 
given subject. 
AEs with an onset date during screening (prior to study drug dosing) will be presented only in a 
data listing. 
3.16.1.1. Adverse Event Overall Summary 
An overall summary table will be provided which summarizes the number and percentage of 
subjects in each treatment group with any TEAE, any treatment-related TEAE (ie, possibly or 
definitely related), any severe TEAE, any TEAE leading to dose reduction, any TEAE leading to 
study discontinuation, any serious TEAE, and any TEAE resulting in death.   
3.16.1.2. Adverse Events Resulting in Study Drug Dose Reductions 
A summary table of TEAEs resulting in study drug dose reductions will be presented.  The first 
line of the table will display the overall frequency for each treatment group column.  Note that 
subjects randomized to the placebo and NBI-98854 40 mg treatment groups who have a reported 
dose reduction actually remain on the randomized dose, while subjects randomized to the 
NBI-98854 80 mg treatment group will have an actual dose reduction. 
A listing of TEAEs resulting in a study drug dose reduction will be provided.  This listing will 
include subject, treatment group, study day of the dose reduction, and additional information 
from the AE eCRF.  
3.16.1.3. Adverse Events Resulting in Premature Study Discontinuation 
A summary table of TEAEs resulting in premature study discontinuation will be presented.  The 
first line of the table will display the overall frequency for each treatment group column. 
A listing of TEAEs resulting in premature study discontinuation will be included in the study 
report as a table.  The listing will include subject, treatment group, last treatment received prior 
to the onset time of the TEAE leading to discontinuation, study day of the discontinuation, and 
both the PT and reported (verbatim) term for all TEAEs that resulted in the premature study 
discontinuation. 
3.16.1.4. Deaths and Other Serious Adverse Events  
The frequency of serious adverse events (SAEs) will be summarized using the approach 
described in Section 3.16.1.3.  The table format for the SAE tables will match those used for the 
TEAE discontinuation tables.   Deaths will be presented in a listing only.   
Listings of SAEs and deaths will be provided.  These listings will include subject, treatment 
group, last treatment received prior to the onset time of the SAE or the TEAE leading to death, 
study day of the death or SAE onset, and all other AE-specific information reported on the AE 
eCRF. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
29 
 
3.16.2. 
Clinical Laboratory Data 
The hematology, clinical chemistry, and prolactin data will be summarized with descriptive 
statistics by treatment group at each scheduled visit from screening (from Day -1 for prolactin) 
through Week 10.  Both observed values and changes from baseline (Day -1, or screening if the 
Day -1 value is missing) will be summarized.   
The prolactin data will be summarized by visit and treatment group for each gender separately, in 
addition to the summaries described above. 
Shift tables will be presented for selected clinical laboratory variables based on the reference 
range-based categories of “Low,” “Normal,” or “High.”  An observed clinical laboratory variable 
value will be assigned to one of these three categories according to the reference ranges provided 
by the central clinical laboratory.   
Each shift table will have three rows and three columns, with rows reflecting the reference range 
category at baseline, and columns reflecting the reference range category at Week 8.  Subjects 
with missing data for a clinical laboratory variable at either baseline or at Week 8 will not be 
included in the table for that variable.  The number and percentage of subjects in each shift 
category will be displayed in the table. 
Shift tables will be presented for the following clinical laboratory variables:  aspartate 
transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), total 
bilirubin, creatine kinase, creatinine, blood urea nitrogen, prolactin, white blood cell count, 
absolute neutrophil count, hemoglobin, and platelet count. 
Summaries of sponsor-defined potentially clinically significant (PCS) values will be presented 
for the following clinical laboratory variables:  ALT, AST, creatinine kinase, GGT, total 
bilirubin, white blood cell count, absolute neutrophil count, creatinine, and BUN.  The number 
and percentage of subjects with PCS values that are reported at any postbaseline visit (scheduled 
or unscheduled) will be summarized by treatment group in summary tables.  The criteria for 
identifying PCS clinical laboratory values are provided in Table 4. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
30 
 
Table 4: 
Potential Clinically Significant Criteria for Clinical Laboratory Variables 
Variable  
PCS Threshold 
ALT 
>3 x ULN (upper limit of normal) 
AST 
>3 x ULN 
Creatine kinase 
>5 x ULN 
GGT 
>3 x ULN 
Total bilirubin 
>1.5 x ULN 
White blood cell count 
≤2.8 x 1000/µL 
Absolute neutrophil count 
<1.5 x 1000/µL 
Creatinine 
>1.5 x Day -1 value or > 1.5 x ULN 
BUN 
>30 mg/dL (> 10.71 mmol/L) 
A listing of subjects with PCS values at any postbaseline visits for any of the variables listed in 
the table above will be presented.  The listing will include subject, treatment group, visit, study 
day, and, for each subject, all laboratory results (including all scheduled and unscheduled visits) 
for the variables with a PCS value for that subject.  Values that meet the PCS criteria will be 
flagged with an asterisk in the listing. 
Scatter plots of selected variables will be created which display Week 8 values vs. baseline 
values.  Each plot will include a 45 degree (“y=x”) reference line.  The plots will be generated by 
treatment group for ALT, AST, creatine kinase, GGT, total bilirubin, and prolactin. 
Additional graphs will be presented for the prolactin data.  These graphs will display mean 
(±SEM) prolactin values for each treatment group at each scheduled visit (Day -1 through Week 
10) in a line graph layout.  A separate graph will be presented for each gender, and each graph 
will be annotated with the reference range lower and upper limits displayed as horizontal dashed 
lines. 
The clinical laboratory data listings located in Section 16.2 of the study report will include 
associated reference ranges (if provided).  In addition, values outside the reference range will be 
flagged as “L” if below the lower limit of normal and as “H” if above the upper limit of normal.  
There will also be a flag for clinical significance based on the investigator’s assessment of out-
of-range values.  The urinalysis data will be presented in data listings only. 
Repeat clinical laboratory samples may be collected at any time during this study due to either 
missing or abnormal results.  The general rule for summarizing these data is to include the 
original sample results in summary tables and graphs.  One exception to this rule is when there 
are missing results from the original samples at screening – in this situation, the results of a 
repeat screening sample will be substituted for the missing results in summary tables and graphs.  
All sample results (original and repeat) will be included in data listings. 
 
 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
31 
 
3.16.3. 
Physical Examination and Weight 
Clinically significant physical examination findings will be presented by subject and visit in a 
listing.  The listing will include subject, visit at which the finding was reported, study day, 
treatment group, and the clinically significant finding.  
Body weight, which is measured during the physical examination, will be summarized in units of 
kilograms with descriptive statistics (both observed values and changes from baseline [Day -1, or 
screening if the Day -1 value is missing]) by treatment group at each scheduled visit from 
screening through Week 10.   
3.16.4. 
Vital Signs 
The vital signs data, including orthostatic blood pressures and heart rate (calculated as standing 
value minus supine value), will be summarized with descriptive statistics by treatment group at 
each scheduled visit from screening through Week 10.  Both observed values and changes from 
baseline (Day -1, or screening if the Day -1 value is missing) will be summarized. 
Sponsor-defined PCS values for systolic blood pressure, diastolic blood pressure, and heart rate 
will be summarized by treatment group.  The number and percentage of subjects with PCS 
values at any postbaseline visit (scheduled or unscheduled) will be presented in the summary 
tables.  The criteria for identifying PCS vital signs values are provided in Table 5. 
Table 5: 
Potentially Clinically Significant Criteria for Vital Signs 
Variable Name 
PCS – Low if: 
PCS – High if: 
Observed 
Value is: 
 
AND 
Decrease from 
Baseline is: 
Observed 
Value is: 
 
AND 
Increase from 
Baseline is: 
Systolic Blood 
Pressure 
<90 mmHg 
 
≥20 mmHg 
>180 mmHg 
 
≥20 mmHg 
Diastolic Blood 
Pressure 
<50 mmHg 
 
≥10 mmHg 
>105 mmHg 
 
≥15 mmHg 
Heart Rate 
<50 bpm 
 
≥15 bpm 
>120 bpm 
 
≥15 bpm 
Note that both supine and standing values of blood pressures and heart rate at all postbaseline 
visits will be included in the identification and summary of PCS values. 
A listing of vital signs data at all visits (scheduled and unscheduled) for subjects with PCS values 
will be presented.  The listing will include subject, treatment group, visit, study day, systolic 
blood pressure (supine and standing), diastolic blood pressure (supine and standing), and heart 
rate (supine and standing).  Values that meet the PCS criteria will be flagged with an asterisk in 
the listing. 
3.16.5. 
Electrocardiogram 
The triplicate values of the quantitative ECG variables (heart rate, PR interval, QRS duration, 
QT interval, and Fridericia’s correction of QT interval [QTcF]) measured at each visit will be 
averaged for the purpose of analysis.  For the overall assessment categorical variable (the 
investigator’s assessment of the ECG as Normal, Abnormal not Clinically Significant, or 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
32 
 
Abnormal Clinically Significant), which is also reported in triplicate, the value that represents 
the greatest degree of abnormality will be used in all summary tables. 
The ECG variables will be summarized with descriptive statistics (frequency tables for the 
overall assessment categorical variable) by treatment group at each scheduled visit from 
screening through Week 10.  Both observed values and changes from baseline (Day -1, or 
screening if the Day -1 value is missing) will be summarized (for the overall categorical 
assessment, only observed values will be summarized).   
Categorical summaries will be presented for the QT and QTcF interval data.  For these 
summaries, a subject’s highest reported postbaseline value will be used to determine in which 
category(s) the subject will be counted.   
Two categorical summaries will be presented for the QT and QTcF intervals (each interval will 
be summarized separately).  For the first summary, the number and percentage of subjects in 
each treatment group whose highest reported QT/QTcF postbaseline value meets the following 
thresholds will be summarized: 
 Greater than 450 msec 
 Greater than 480 msec 
 Greater than 500 msec 
The second categorical summary will display the number and percentage of subjects in each 
treatment group whose largest QT/QTcF increase from their baseline value meets the following 
thresholds:  
 Greater than 30 msec 
 Greater than 60 msec 
3.16.6. 
Columbia-Suicide Severity Rating Scale (C-SSRS) 
The C-SSRS data will be presented in the following summaries: 
 Screening/lifetime assessment by treatment group and for all subjects combined 
 Screening/past 1 year assessment by treatment group and for all subjects combined 
 Baseline (Day -1) assessment by treatment group and for all subjects combined 
 All postbaseline assessments (Day 1 through Week 10) by treatment group 
Each summary will display the number and percentage of subjects who report “Yes” to specific 
C-SSRS items or categories of items (a category is assigned a “Yes” value if a “Yes” is reported 
for any item in the category).  These C-SSRS items and categories are as follows: 
 Suicidal Ideation Items 
(1) 
Wish to be dead 
(2) 
Non-specific active suicidal thoughts 
(3) 
Active suicidal ideation with any methods (not plan) without intent to act 
(4) 
Active suicidal ideation with some intent to act, without specific plan 
(5) 
Active suicidal ideation with specific plan and intent 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
33 
 
 Suicidal Ideation Category:  Any of items (1) through (5) 
 Suicidal Behavior Items (not reported for the Screening/past 1 year assessment) 
(6) 
Preparatory acts or behavior 
(7) 
Aborted attempt 
(8) 
Interrupted attempt 
(9) 
Non-fatal suicide attempt 
(10) 
Completed suicide 
 Suicidal Behavior Category:  Any of items (6) through (10) 
 Suicidal Ideation or Behavior Category:  Any of items (1) through (10) 
For the “all postbaseline assessments” summary, each subject’s C-SSRS responses for all 
postbaseline assessments during the study (including assessments at both scheduled and 
unscheduled visits) will be evaluated, and a “Yes” response for any assessment will be 
considered as a “Yes” for the subject. 
In addition to the summaries described above, shift tables comparing postbaseline suicidal 
ideation scores to baseline scores will be presented.  The shift table scores are defined as the 
following: 
0=No suicidal ideation 
1=Wish to be dead 
2=Non-specific active suicidal thoughts 
3=Active suicidal ideation with any methods (not plan) without intent to act 
4=Active suicidal ideation with some intent to act, without specific plan 
5=Active suicidal ideation with specific plan and intent 
The shift tables will display the number and percentage of subjects within each cell of a 6 x 6 
table for each treatment group, with the rows representing the baseline score and the columns 
representing the maximum score recorded across all postbaseline assessments (including both 
scheduled and unscheduled visits). Subjects missing either a baseline score or all postbaseline 
scores will not appear in the table.  
A summary listing of individual subject data for the C-SSRS will be provided which lists data at 
all visits for subjects with a positive response for suicidal ideation, suicidal behavior, or self-
injurious behavior without suicidal intent at any postbaseline visit during the study.   The listing 
will be in the form of a table, with each row representing a subject visit (scheduled and 
unscheduled).  The listing will include subject, visit, timepoint (for screening assessments), study 
day of the visit, treatment group, and a column for each suicidal ideation item (1 – 5), each 
suicidal behavior item (6 – 10), and a final column for self-injurious behavior without suicidal 
intent.  The cells of the table will be populated with “Y” or “N,” representing either a positive or 
negative response, respectively, for each item in the table (ie, for each column of the table). 
3.16.7. 
Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) 
Amendment 3 of the clinical study protocol added the ESRS-A assessment tool to evaluate 
extrapyramidal symptoms, therefore it is expected that data will be available for all subject visits 
that take place after the date of the IRB approval at each site. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
34 
 
The ESRS-A assesses 4 types of movement disorders: parkinsonism, dystonia, akathisia, and 
tardive dyskinesia.  The ESRS-A consists of four subscales, one for each type of movement 
disorder.  The ESRS-A contains 10 items to evaluate parkinsonism, 6 items to evaluate dystonia, 
6 items to evaluate dyskinesia, and 2 items to evaluate akathisia.  Each item score can range from 
0 to 5, for a maximum possible parkinsonism score of 50, maximum possible dystonia score of 
30, maximum possible dyskinesia score of 30, and maximum possible akathisia score of 10.  A 
Clinical Global Impression of Severity (CGI-S) is also completed for each type of movement 
disorder, and is also is scored on a 0 to 5 scale.  The ESRS-A is administered at baseline (Day -1) 
and at Weeks 2, 4, 6, 8, and 10. 
The subscale scores for each type of movement disorder (parkinsonism, akathisia, dystonia, and 
tardive dyskinesia) will be calculated as the sum of the scores of the individual items comprising 
each subscale.  The overall total score will be calculated as the sum of each of the subscale 
scores.  If any one of the items is not scored (ie, has a missing value), the associated subscale 
score and total score will be set equal to missing.  The CGI-S scores will be summarized 
separately from the subscale scores. 
Each of the subscale scores for parkinsonism, akathisia, dystonia, and tardive dyskinesia, and the 
overall total score at each visit (Day -1 and Weeks 2, 4, 6, 8, and 10) will summarized with 
descriptive statistics by treatment group. Changes from baseline at each post-baseline visit will 
also be summarized. 
The CGI-S scores for each subscale at each visit (Day -1 and Weeks 2, 4, 6, 8, and 10) will 
summarized with descriptive statistics by treatment group. Changes from baseline at each post-
baseline visit will also be summarized. 
3.16.8. 
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) 
The Y-BOCS is a semi-structured interview designed to rate the severity of obsessive and 
compulsive symptoms.   
The Y-BOCS obsession subtotal score is calculated as the sum of the scores for items 1 through 
5 of the Y-BOCS scale (excluding item 1b), and the Y-BOCS compulsion subtotal score is 
calculated as the sum of the scores for items 6 through 10 of the Y-BOCS scale (excluding item 
6b).  The Y-BOCS total score is the sum of the obsession and compulsion subtotal scores.  Each 
item score ranges from 0 to 4, with a maximum possible obsession subtotal score of 20, a 
maximum possible compulsion subtotal score of 20, and a maximum possible total score of 40.  
If any one of these 10 items is not scored (ie, has a missing value), the associated subtotal score 
and total score will be set equal to missing. 
The subtotal scores for obsession and compulsion, and the total score at each visit (screening, 
Day -1, and Weeks 2, 4, 6, 8, and 10) will summarized with descriptive statistics by treatment 
group. Changes from baseline (Day -1) at each postbaseline visit will also be summarized. 
3.16.9. 
Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D-
17) 
The SIGH-D-17 is a 17-item, semi-structured questionnaire for rating depression and is 
administered by the investigator (or designee).  The SIGH-D-17 total score is calculated as the 
sum of the 17 items making up the SIGH-D-17.  Each item is scored on a 3, 4, or 5-point scale.  
The maximum possible total score is 53.  If any one of the 17 items is not scored (ie, has a 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
35 
 
missing value), the total score will be set equal to missing.  Note that a score of 3 for Item 8 (loss 
of weight) represents “not assessed”, and should be ignored in calculating the total score. 
The total score at each visit (screening, Day -1, and Weeks 2, 4, 6, 8, and 10) will be summarized 
with descriptive statistics by treatment group.  Changes from baseline (Day -1) at each 
postbaseline visit will also be summarized. 
3.16.10. 
Prior and Concomitant Medications 
Prior medications and concomitant medications will be summarized by WHO Drug Anatomical 
Therapeutic Chemical Classification (ATC) Level 3 category (or Level 2 if there is not an 
applicable Level 3 category) and preferred name.  
Medications will be assigned to one or two study periods (prestudy or during screening vs. 
during the treatment period or posttreatment, follow-up period) based on the medication start and 
stop dates relative to the study drug dosing. For example, medications that were started and 
stopped prior to the date of the first dose of study drug will be assigned to the prestudy/screening 
period only, while medications started prior to the first dose of study drug and either stopped 
during the study or indicated as “ongoing” will be assigned to both the prestudy/screening and 
treatment/follow-up periods. A given medication can therefore be assigned to one or two study 
periods in the tabular summaries, depending on its start and end dates.  
The number and percentage of subjects using medications in each WHO Drug ATC category 
(Level 3/preferred name) will be summarized by treatment group and study period as described 
in the next paragraph. A subject may take the same medication more than once or multiple 
medications for a subject may be classified under the same ATC level or preferred name. A 
subject is counted only once for each level of medication classification within a summary.  
The summary of medications taken prestudy or during screening will be presented by treatment 
group.  An “all subjects” column will be included in this summary.  Medications taken during the 
study after the initiation of dosing (ie, during the treatment or follow-up periods) will be 
summarized by treatment group. 
3.17. 
Additional Data Presentations 
3.17.1. 
Inclusion and Exclusion Criteria 
Inclusion and exclusion criteria confirmation results will be presented in a data listing by subject. 
3.17.2. 
Serology Test Results 
Serology assessments (ie, Human immunodeficiency virus antibody [HIV-Ab], Hepatitis B 
surface antigen [HBsAg], and Hepatitis C antibody [HCV-Ab]) collected at screening will be 
reviewed at the study site to ensure the entry criteria are met.  The HBsAg and HCV-Ab test 
results will be presented in a listing by subject.  The results of the HIV-Ab test will not be listed, 
but will be kept on file at the study site. 
3.17.3. 
Pregnancy Test Results 
Serum and urine pregnancy test results will be presented in a listing by subject. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
36 
 
3.17.4. 
Urine Drug Screen and Alcohol Breath Test 
Urine drug screen and alcohol breath test results will be presented in a listing by subject. 
4. 
DEVIATIONS FROM PROTOCOL PLANNED ANALYSIS 
The methods of analysis described in this SAP are generally consistent with the statistical 
methods described in the clinical study protocol (Amendment 3).  The methods of analysis have 
been changed for two efficacy endpoints:  the CGI-TS-Improvement score and the RTRS total 
score.  The MMRM analysis was specified in the protocol for both of these endpoints.  In this 
SAP, the ANOVA is specified for the CGI-TS-Improvement score, and the ANCOVA is 
specified for the RTRS total score.  Sensitivity analyses have been added to the SAP for the 
primary efficacy endpoint.  In addition, the CGI-TS-Improvement score mean change from 
baseline to Week 8 has been identified as the key secondary efficacy endpoint, and the fixed-
sequence testing procedure has been included.  The SAP includes additional endpoints and data 
summaries not mentioned in the study protocol, including the TTS responder analysis and the 
PCS value summaries for clinical laboratory data and vital signs. 
5. 
PERFORMANCE QUALIFICATION OF SAS® PROGRAMS 
The analysis and summary of data from this study will be performed using SAS® 9.3 (or a later 
release if available).  All SAS® programs used in the production of statistical analyses, tables, 
listings, and figures described in this SAP will undergo performance qualification (verification 
that the program produces the intended output) in accordance with department standard operating 
procedures.  The performance qualification may include independent programming and/or peer 
review of the SAS® log files.  In addition, tables, figures, listings, and statistical analysis output 
will be independently reviewed for completeness and accuracy. 


Neurocrine Biosciences, Inc. 
NBI-98854-1505 Statistical Analysis Plan 
37 
6.
REFERENCES
ClinicalTrials.gov Identifier: NCT01727700. Otsuka Pharmaceutical Development & 
Commercialization, Inc. Study evaluating the safety and efficacy of fixed-dose once-daily 
aripiprazole in children and adolescents with Tourette’s Disorder 
https://www.clinicaltrials.gov/ct2/show/NCT01727700?term=NCT01727700&rank=1 [Accessed 
05 June 2015]. 
Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled 
study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 
Jan;81(1):70-3. 
LaVange LM.  The role of statistics in regulatory decision making.  Therapeutic Innovation and 
Regulatory Science.  2014; 48(1) 10-19. 
O’Kelly M, Ratitch B. Clinical Trials with Missing Data: A Guide for Practitioners. West 
Sussex, United Kingdom: John Wiley & Sons, Ltd. 2014; 292-297, 309-310. 
Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, et al. A multicenter, randomized, 
double-blind, placebo-controlled study of aripiprazole in children and adolescents with 
Tourette’s disorder. J Clin Psychiatry. 2013;74(8):e772-80.